Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Hypochondrogenesis. Core disease mechanisms, molecular and cellular pathwa...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 20
• Snippets retrieved: 20

Relevant Papers

[1] New therapeutic targets in rare genetic skeletal diseases

• Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
• Year: 2015
• Venue: Expert Opinion on Orphan Drugs
• URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
• DOI: 10.1517/21678707.2015.1083853
• PMID: 26635999
• PMCID: 4643203
• Citations: 37
• Influential citations: 1
• Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Evidence snippets:
• Snippet 1 (score: 0.453) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[2] Organoids in gastrointestinal diseases: from bench to clinic

• Authors: Qinying Wang, Fanying Guo, Qinyuan Zhang, Tingting Hu, Yutao Jin et al.
• Year: 2024
• Venue: MedComm
• URL: https://www.semanticscholar.org/paper/9b8880d8b9d45670da950197d7e353794f51d09e
• DOI: 10.1002/mco2.574
• PMID: 38948115
• PMCID: 11214594
• Citations: 12
• Summary: A comprehensive and systematical depiction of organoids models is drawn, providing a novel insight into the utilization of organoids models from bench to clinic and clinical adhibition.
• Evidence snippets:
• Snippet 1 (score: 0.407) > Organoids models offer a robust platform for investigating the potential mechanisms of GI diseases and evaluating potential therapeutic interventions.By culturing organoids derived from patients' tissues or stem cells, researchers can delve into disease-specific cellular and molecular pathways, encompassing aberrant cell signaling, perturbed immune responses, and dysfunctional metabolic processes.These disease-specific phenotypes enable the study of disease progression, screening of prospective therapeutics, as well as identification of novel drug targets and mechanisms of action for GI diseases in a clinically relevant context.

[3] COL2A1 Gene Mutations: Mechanisms of Spondyloepiphyseal Dysplasia Congenita

• Authors: R. Nenna, A. Turchetti, G. Mastrogiorgio, F. Midulla
• Year: 2019
• Venue: The Application of Clinical Genetics
• URL: https://www.semanticscholar.org/paper/11570930acf0acf11d460fbedbda787a1c71e000
• DOI: 10.2147/TACG.S197205
• PMID: 31824186
• PMCID: 6900288
• Citations: 33
• Influential citations: 2
• Summary: The COL2A1 gene consists of 54 exons spanning over 31.5 kb and encodes for type II collagen, which is the main component of hyaline cartilage extracellular matrix, nucleus pulposus of intervertebral discus, vitreous humor of the eye and inner ear structure and more.
• Evidence snippets:
• Snippet 1 (score: 0.405) > Missense mutations leading to other amino acids than glycine substitution causes generally milder phenotype due to impairment in protein stability, and subsequent damage in helical structure and proper function of type II collagen. > Haploinsufficiency is a mechanism due to non-sense substitutions or out-of-frame deletions, resulting in premature stop codons which cause reduced synthesis of normal collagen. These mutations are associated with milder phenotypes. > Furthermore, phenotypic variation is likely caused by environmental factors and the polymorphisms in diseasemodifying genes and/or regulatory elements. > Type II collagenopathies clinical features show a wide range of severity and complexity. > Moreover, several type II collagenopathies clinical features are shared by other syndromes due to defects in other components of cartilage (eg, otospondylomegaepiphyseal dysplasia caused by COL11A2 mutation, multiple epiphyseal dysplasia principally caused by COMP mutation). 10,11 henotypic overlap in COL2A1-related disorders and wide inter-and intra-familiar phenotypic variation have been commonly reported. > At one end of the spectrum, achondrogenesis type II (ACG2)/hypochondrogenesis and platyspondylic lethal skeletal dysplasia, Torrance type (PLSDT) are perinatally lethal conditions. They are characterized by micromelia, narrow chest with pulmonary hypoplasia, absent ossification of vertebras bodies and sacrum, Pierre Robin sequence and several visceral anomalies. At the other end of the spectrum are listed some conditions typical of adolescent or adult age: avascular necrosis of the femoral head (ANFH), Legg-Calvè-Perthes disease, early-onset osteoarthritis (OA), Strickler syndrome type1 (STL1), vitreoretinopathy with phalangeal epiphyseal dysplasia (VPED). These conditions are characterized by normal stature and early development of arthrosis or ocular defects.

[4] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

• Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
• Year: 2025
• Venue: Journal of Veterinary Internal Medicine
• URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
• DOI: 10.1111/jvim.70139
• PMID: 40492724
• PMCID: 12150350
• Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
• Evidence snippets:
• Snippet 1 (score: 0.390) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[5] Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response

• Authors: P. Mesdom, R. Colle, É. Lebigot, S. Trabado, Eric Deflesselle et al.
• Year: 2020
• Venue: Current Neuropharmacology
• URL: https://www.semanticscholar.org/paper/79368e365458486de96794333613c12a6063bf54
• DOI: 10.2174/1570159X17666191021141057
• PMID: 31631822
• PMCID: 7327943
• Citations: 12
• Summary: This review highlights the great and still underused potential of HDF, which stands out as a very promising tool in the understanding of MDD and AD mechanisms of action.
• Evidence snippets:
• Snippet 1 (score: 0.379) > Background: Human dermal fibroblasts (HDF) can be used as a cellular model relatively easily and without genetic engineering. Therefore, HDF represent an interesting tool to study several human diseases including psychiatric disorders. Despite major depressive disorder (MDD) being the second cause of disability in the world, the efficacy of antidepressant drug (AD) treatment is not sufficient and the underlying mechanisms of MDD and the mechanisms of action of AD are poorly understood. Objective The aim of this review is to highlight the potential of HDF in the study of cellular mechanisms involved in MDD pathophysiology and in the action of AD response. Methods The first part is a systematic review following PRISMA guidelines on the use of HDF in MDD research. The second part reports the mechanisms and molecules both present in HDF and relevant regarding MDD pathophysiology and AD mechanisms of action. Results HDFs from MDD patients have been investigated in a relatively small number of works and most of them focused on the adrenergic pathway and metabolism-related gene expression as compared to HDF from healthy controls. The second part listed an important number of papers demonstrating the presence of many molecular processes in HDF, involved in MDD and AD mechanisms of action. Conclusion The imbalance in the number of papers between the two parts highlights the great and still underused potential of HDF, which stands out as a very promising tool in our understanding of MDD and AD mechanisms of action

[6] Recent Evidences of Epigenetic Alterations in Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review

• Authors: R. Ragusa, Pasquale Bufano, A. Tognetti, M. Laurino, Chiara Caselli
• Year: 2025
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/2660cdbbe1f205c631fe890e5c6a3c8d9b81ce5f
• DOI: 10.3390/ijms26062571
• PMID: 40141213
• PMCID: 11942187
• Citations: 3
• Summary: A systematic review of the latest knowledge on epigenetic modifications that characterize COPD, summarizing epigenetic factors that could serve as potential novel biomarkers and therapeutic targets for the treatment of COPD patients.
• Evidence snippets:
• Snippet 1 (score: 0.376) > The papers included were clustered according to epigenetic mechanisms involved in COPD (molecular and cellular processes, as biomarker or therapeutic target). Tables 4-9 describe the extracted information, including the following: Study = name of first author et al., year; Country (Region) = where the study took place; Number of participants = sample size; Type of sample = biological sample employed; Gene affected = gene or group of genes whose expression can be "regulated" by epigenetic mechanisms; Epigenetic alteration = type of epigenetic alteration observed in the presence of disease; Activity in COPD = involvement of epigenetic elements in different molecular and cellular mechanisms associated with COPD; and Role of epigenetic mechanisms = epigenetic modifications that can be used to explain the pathophysiology of COPD or as biomarkers and therapeutic targets.

[7] Direct Sarcomere Modulators Are Promising New Treatments for Cardiomyopathies

• Authors: O. Tsukamoto
• Year: 2019
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/07467943fe92ce135b52ded5e5dea2bfc2ddf179
• DOI: 10.3390/ijms21010226
• PMID: 31905684
• PMCID: 6982115
• Citations: 16
• Summary: The direct inhibition of sarcomere contractility may be able to suppress the development and progression of HCM with hypercontractile mutations and improve clinical parameters in patients with HCM, and direct activation of sar COMs modulators that can positively influence the natural history of cardiomyopathies represent promising treatment options.
• Evidence snippets:
• Snippet 1 (score: 0.372) > Hereditary DCM can be caused by single point mutations in sarcomere proteins. However, the link between point mutations and clinical phenotypes in DCM is not thoroughly understood in most cases. Recent advances in biochemical, biophysical, stem cell, and gene editing technologies have provided a better understanding of the molecular mechanisms through which the initial insult in DCM (i.e., mutations in a sarcomere protein) induces alterations in cellular organization and contractility, resulting in disease phenotypes. In particular, hiPSC-CMs and genetically modified animals are excellent models because they can capture the initial molecular phenotype that occurs before major compensatory mechanisms mask it.

[8] Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation

• Authors: Hao Xiong, Jinsheng Guo
• Year: 2025
• Venue: Pharmaceuticals
• URL: https://www.semanticscholar.org/paper/76e92127053136900f7e3f10e2c9278251ced5d2
• DOI: 10.3390/ph18040507
• PMID: 40283943
• PMCID: 12030350
• Citations: 7
• Summary: HSC-targeted approaches using specific surface markers and receptors may enable the selective delivery of drugs, oligonucleotides, and therapeutic peptides that exert optimized anti-fibrotic and anti-HCC effects.
• Evidence snippets:
• Snippet 1 (score: 0.370) > Significant progress has been made in elucidating the cellular and molecular mechanisms of liver fibrosis; however, only a few findings have been successfully translated into clinical applications. Firstly, the high cost of drug development and target validation necessitates prolonged timelines and substantial financial investment. Secondly, as regulatory requirements become more stringent, there is an increasing demand for drugs with well-defined clinical efficacy and safety profiles. Moreover, the efficacy observed in animal models often fails to fully translate to clinical settings due to differences in pharmacokinetics, extracellular matrix (ECM) cross-linking, and disease pathophysiology. Despite advancements in anti-fibrotic drug development, accurately identifying ideal noninvasive biomarkers for fibrotic activity and establishing consensus on optimal clinical endpoints remain significant challenges [113,114]. > Currently, addressing the underlying cause remains the only proven strategy to halt or reverse liver fibrosis progression, while the development of effective anti-fibrotic therapies continues to pose a major challenge in liver disease management. Over the past few decades, substantial progress has been made in elucidating the cellular and molecular mechanisms underlying liver fibrosis. Liver fibrosis is a complex pathological change involving multiple cells, factors, and pathways, and the study of the cellular and molecular mechanisms of its occurrence and development provides an important theoretical basis and therapeutic target for clinical drug development. It is anticipated that improved animal models and well-designed clinical trials will facilitate the successful translation of anti-fibrotic research into effective clinical treatments in the near future.

[9] Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?

• Authors: E. Courcelles, J. Boissel, J. Massol, I. Klingmann, R. Kahoul et al.
• Year: 2022
• Venue: Frontiers in Medical Technology
• URL: https://www.semanticscholar.org/paper/877d5b1b75599745f704a9c8371f74601ff17e2f
• DOI: 10.3389/fmedt.2022.810315
• PMID: 35281671
• PMCID: 8907708
• Citations: 6
• Summary: Light is shed on different stakeholder's contributions and needs in the appraisal phase and how mechanistic modeling strategies and reporting can contribute to this effort to implement mechanistic models central in the evidence generation, synthesis, and appraisal of HTA so that the totality of mechanistic and clinical evidence can be leveraged by all relevant stakeholders.
• Evidence snippets:
• Snippet 1 (score: 0.369) > A second limitation in HTA is the fact that currently population (and sometimes stratified) medicine is pursued during clinical Uncertainty not completely addressed in competent authority assessment report Example use of MIDD relevant to address uncertainty potentially also during HTA What is the optimal dosage in the clinical context? > Physiologically based pharmacokinetic models can investigate dosing-regimens relevant for regulatory review and product labels (9) and can also mimic real-life adherence to prescribed treatment regimens (see also below) or pharmacology-relevant characteristics of special populations as well as drug-drug interactions. > What is the duration of the effectiveness, especially with chronic use of a treatment? > Mechanistic models can predict the long-term disease progression by extrapolation of shorter-term findings under the constraints of how the components of the system function (and these constraints convey biological plausibility by design). An example is the use of a mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin, and gliclazide on disease processes underlying Type 2 Diabetes Mellitus (10). Another example is prediction of long-term outcomes by short-term marker data as demonstrated by a semi-mechanistic approach in context of osteoporosis treatment (11). > What is the efficacy for relevant clinical outcomes? > Mechanistic models combined with pharmacometric approaches can translate findings for one outcome to a range of other outcomes. An example of survival modeling on the back of a mechanistic description is the modeling framework for CD19-Specific CAR-T cell immunotherapy using a quantitative systems pharmacology model (12). > What is the size of the clinical effect dependent on patient characteristics and extrinsic factors? > Data-driven modeling techniques can capture correlation within clinical data. Describing the clinical effect of a drug can also be based on mechanistic considerations. Such models either (a) link disease phenotypes to increasingly granular mathematical representations of pathophysiologic processes (top-down approach) or (b) derive functional, computable cellular networks from the molecular building blocks of genes and proteins to elucidate the impact of pathologic or therapeutic alterations on network operating states and hence clinical phenotype (bottom-up) [

[10] Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers

• Authors: W. Tulalamba, T. Janvilisri
• Year: 2012
• Venue: International Journal of Cell Biology
• URL: https://www.semanticscholar.org/paper/307cb9186444d9dad6e2e3b53763be0de76de186
• DOI: 10.1155/2012/594681
• PMID: 22500174
• PMCID: 3303613
• Citations: 93
• Influential citations: 5
• Summary: The molecular signaling pathways in the NPC are discussed for the holistic view of NPC development and progression and the important insights toward NPC pathogenesis may offer strategies for identification of novel biomarkers for diagnosis and prognosis.
• Evidence snippets:
• Snippet 1 (score: 0.365) > In the pregenomic eras, highly integrated and complex circuitry of molecular signaling in NPC pathogenesis was only partially understood. Over the past decade, the knowledge of the molecular mechanisms in NPC carcinogenesis has been rapidly accumulated. Dysregulation and abnormal protein expression of molecules in certain signaling pathways involved in cellular functions including proliferation, adhesion, survival, and apoptosis has been demonstrated in the NPC cells. Detailed information on the complex network in signaling pathway leading to a coordinated pattern of gene expression and regulation in NPC will undoubtedly provide important clues to develop novel prognostic and therapeutic strategies for this cancer. Refining molecular markers into clinically relevant assays may assist in the detection of NPC in asymptomatic patients, as well as stage classification and monitoring disease progression and treatments. Furthermore, selective regulation of particular proteins targeting cancer cell proliferation, invasion, and apoptosis is a hopeful prospect for future anticancer therapy that slow disease progression and improve survival.

[11] Chondroprotective Factors in Osteoarthritis: a Joint Affair

• Authors: J. Mimpen, Sarah J B Snelling
• Year: 2019
• Venue: Current Rheumatology Reports
• URL: https://www.semanticscholar.org/paper/8e9758d948f6d821fc10bacf365a2bf1e9efd5f4
• DOI: 10.1007/s11926-019-0840-y
• PMID: 31227927
• PMCID: 6588640
• Citations: 26
• Influential citations: 1
• Summary: Chondroprotection requires a whole joint approach, stratification of patient groups, and use of patient-relevant end points, while using modern technologies and recent knowledge to re-visit unsuccessful therapeutics from the past.
• Evidence snippets:
• Snippet 1 (score: 0.363) > Cellular or molecular signatures may not have functional effects on cartilage damage or OA pathobiology and may instead simply postcode a disease state or subtype. Therefore, successful delivery of chondroprotection relies on well-conducted functional studies and on the extension of cross-sectional and longitudinal studies of OA endotypes-all informed by clinical signs and risk factors. Tissues across the whole joint plus urine, blood, and synovial fluid should be incorporated. Cellular and molecular signatures of tissues obtained from diseased joints, healthy joints and joints following t herapeutic intervention are also essential. These signatures will enable identification of underlying mechanisms of disease and produce meaningful readouts to assess whether an intervention results in a "healthy" or "effectively treated" signature. The use of the spectrum of relevant tissues and fluids allows more robust endotype identification, while identifying less invasive surrogates for tissuebased signatures. Stratification panels will undergo continuous evolution, changing not only with disease subset but also with the stage of cartilage damage and other clinical readouts and risk-factors. The key stratification categories should be applied to studies of disease development and to pre-clinical and clinical drug development pathways. To refine critical stratification measures and identify relevant end points for pre-clinical and clinical studies, nextgeneration sequencing, "omics", and cytometry approaches should be integrated with risk factors, clinical signs and symptoms. Tissue-based end points and stratification measures should be derived using well-phenotyped healthy and diseased tissues from the joint. Where appropriate, embedding tissue collection and analysis within enrolment and outcome stages of clinical trials would inform future studies across the translational cycle Studies of disease mechanisms, drug target identification, and drug testing rely on in vitro and in vivo methods, supplemented with in silico and mathematical modeling, to identify key drivers, stratification sets, and end points. Functional assays and modeling of identified biomarkers, cell types, and molecular signatures will enable validation of potential targets for chondroprotective agents and testing of therapeutic efficacy. Models and end points used in vitro and in vivo need to account for differing endotypes and changing molecular signatures associated with OA progression or cessation. As with human disease, these models should not be cho

[12] Integrative epigenomics, transcriptomics and proteomics of patient chondrocytes reveal genes and pathways involved in osteoarthritis

• Authors: J. Steinberg, G. R. S. Ritchie, T. Roumeliotis, R. Jayasuriya, M. J. Clark et al.
• Year: 2016
• Venue: Scientific Reports
• URL: https://www.semanticscholar.org/paper/24d776d78df1edd8fdb3ef4094650dfcea0dc4f2
• DOI: 10.1038/s41598-017-09335-6
• PMID: 28827734
• PMCID: 5566454
• Citations: 112
• Influential citations: 4
• Summary: Through integration of genome-wide methylation, gene and protein expression data in human primary chondrocytes, consistent molecular players in OA progression that replicated across independent datasets and that have translational potential are identified.
• Evidence snippets:
• Snippet 1 (score: 0.362) > are joint-independent. > Notably, this study is a proof-of-concept for integrative deep molecular phenotyping across methylation, gene expression, and protein abundance. As such, it was not powered to provide an exhaustive list of molecular targets and pathways. Indeed, we estimate that only ~10% of the true differentially expressed genes are statistically significant in this study (Supplementary Fig. S5). The sample size could also affect the degree of overlap and agreement between the methylation, gene expression, and protein abundance (this overlap could also be affected by difficulties in assigning the effects of methylation changes to genes: for example, it is possible that the expression of a gene is affected by methylation changes in a distal enhancer, or that a given gene contains an enhancer region for a different gene, and thus methylation of the first gene also affects the expression of the second). Larger sample sizes will be required for a more powerful characterisation of the molecular changes occurring with disease progression. Moreover, investigations of further OA-relevant cell types (including synoviocytes and adipocytes) will be necessary to identify disease-related changes in other tissues, and the biological mechanisms specific to such tissues. > In summary, the integrative functional genomics approach undertaken here has identified biological changes in disease-relevant tissues, highlighting three genes and several pathways that are involved on all three levels examined. Moreover, the approach identified nine genes with changes on multiple molecular levels that are already targeted by drugs approved for human use, highlighting the potential of discovering targets for intervention. These drugs have established safety profiles and pharmacokinetic data for use in humans, which would shorten the investigative pipeline to clinical use in OA. These agents cover a broad range of mechanisms of action and represent novel investigational targets for 'first in disease' studies of OA progression. Further studies will be necessary to comprehensively characterize the molecular signatures of OA.

[13] Heat Shock Proteins in Oxidative Stress and Ischemia/Reperfusion Injury and Benefits from Physical Exercises: A Review to the Current Knowledge

• Authors: Jakub Szyller, I. Bil-Lula
• Year: 2021
• Venue: Oxidative Medicine and Cellular Longevity
• URL: https://www.semanticscholar.org/paper/4ec4bee9f1b89cdf5a3c513d847990f3cfc18bb8
• DOI: 10.1155/2021/6678457
• PMID: 33603951
• PMCID: 7868165
• Citations: 110
• Influential citations: 2
• Summary: The latest research focuses on determining the role of H SPs in OS, their antioxidant activity, and the possibility of using HSPs in the treatment of I/R consequences, where reactive oxygen species play a major role.
• Evidence snippets:
• Snippet 1 (score: 0.362) > Heat shock proteins play a cytoprotective role under pathological conditions such as cardiovascular diseases. The knowledge about cellular and molecular mechanisms underlying ROS-mediated modulation of HSP expression can help to better understand the pathophysiology of OS, which is associated with the development of many diseases (cardiovascular, neurodegenerative, etc.). I/R injury is considered a major contributor to tissue damage in multiple clinical situations such as myocardial infarction, stroke, and organ transplantation. Oxidative damage is a key factor in the initiation of I/R. HSP expression is highly sensitive to I/R injury. > Understanding the exact mechanisms of HSP and the structure of the protein interaction network can help to better understand the pathophysiology and treatment of many diseases, as well as to develop new drugs. There is a need to understand the relationship between cell pathways-signaling, metabolism, etc. The relationships between HSP and OS discussed in this work seem to be very complicated and not yet fully understood. Data showed that modulation of HSP expression in reperfusion injuries may result in better treatment of myocardial infarction. This can also help to prepare organs for the transplantation.

[14] Bioinformatics analysis of ferroptosis in frozen shoulder

• Authors: Hongcui Zhang, Jiahua Zhou, ZhiHua Liu, Kaile Wang, Hexun Jiang
• Year: 2024
• Venue: BMC Medical Genomics
• URL: https://www.semanticscholar.org/paper/add3fea4459c4cf693f0de24972672a849a78bbc
• DOI: 10.1186/s12920-024-02011-5
• PMID: 39334338
• PMCID: 11428309
• Summary: The results demonstrated that ferroptosis may affect the pathological process of frozen shoulders through these signaling pathways and genes.
• Evidence snippets:
• Snippet 1 (score: 0.361) > Frozen shoulder (FS), also known as adhesive capsulitis, is a chronic condition characterized by pain, stiffness, and restricted range of motion of the shoulder joint [1]. This condition can have a significant impact on patients' quality of life, limiting their ability to perform daily activities and causing significant discomfort [2]. The precise etiology of frozen shoulders remains unclear, however, accumulating evidence suggests that dysregulation of cellular processes, including inflammation and oxidative stress, may play a vital role in its pathogenesis [3]. > In recent years, bioinformatics has made significant progress in understanding the molecular mechanisms underlying various diseases [4]. Bioinformatic tools and techniques have enabled the integration of vast amounts of data generated from different experimental platforms, providing valuable insights into the complex biological processes that lead to disease development [5]. Bioinformatics has revealed novel therapeutic targets and potential drug candidates for various diseases by analyzing gene expression profiles, protein networks, and pathway interactions [6]. > Ferroptosis is a regulatory cell death process driven by iron-dependent lipid peroxidation and is involved in the pathological and physiological processes of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases [7,8]. In this study, we aim to use bioinformatics analyses to investigate the potential role of ferroptosis in the pathophysiology of frozen shoulders. By integrating transcriptomic data from patients with frozen shoulders, we hope to identify the molecular signatures associated with ferroptosis under these conditions. This approach will enable us to gain a more comprehensive understanding of the underlying mechanisms involved in frozen shoulders and the potential role of ferroptosis in its development and progression. This is the first study to explore the complex relationship between ferroptosis and frozen shoulders, and our research may lead to the discovery of novel therapeutic targets that can effectively manage this musculoskeletal condition. By understanding the underlying mechanisms that drive ferroptosis in frozen shoulders, innovative treatment strategies that target these specific pathways can be designed. Such targeted approaches may offer patients more personalized and effective treatment options, leading to improved outcomes and quality of life. Furthermore, our findings could contribute to a better understanding of the pathogenesis of frozen shoulders.

[15] Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data

• Authors: J. Barrett, Megan Cala Pane, Timothy D. Knab, W. Roddy, J. Beusmans et al.
• Year: 2022
• Venue: Frontiers in Pharmacology
• URL: https://www.semanticscholar.org/paper/1b1552b5a3b6bd9f225ecce6435d9972f160e6b4
• DOI: 10.3389/fphar.2022.988974
• PMID: 36313352
• PMCID: 9597633
• Citations: 2
• Summary: A landscape of the data is defined including targeted literature searches and solicitation of neonatal RWD sources for context-of use (COU)-driven models and analysis plans to develop a family of models of BPD in neonates, leveraging previous clinical trial experience and real-world patient data are described.
• Evidence snippets:
• Snippet 1 (score: 0.357) > Techniques to measure biological events and mechanisms have not been delineated or deployed at sufficient scale to provide a comprehensive "map" of the condition. Similarly, clinical events have not been defined other than a variety of short-and long-term endpoints. Clinical observations are not informed by the timing or nature of biological processes or mechanisms. In other conditions, information about the stages of pathophysiology (biological processes) and clinical events inform the development of therapeutic options. Data from biological and clinical sources, summarized in Figure 2, can be combined in "disease progression models" (DPM) that capture the stages of disease development, the timing of the stages, and the extent of variation between individuals in the pathway to disease. DPM are a key tool in drug development allowing rational targeting of interventions and evidencebased planning of clinical trials (Fouarge et al., 2021;Barrett et al., 2022). Here we review the DPM concept applied to strategies for the development of a BPD DPM. This manuscript seeks to both prospectively assess the potential of the clinical real-world data to inform BPD (and therefore, other complications of extreme prematurity) definition and also the potential of utilizing such data to construct models that would inform BPD drug development as a context of use. Selected references identified by this search were supplemented by papers from the authors' collections and identification of additional resources among subject matter experts from the INC. The INC BPD working group and modeling and simulation subteam filtered the literature search results into categories that would include one of the following: relevant data from which model priors could be abstracted, published models of various types (e.g., predictive, descriptive, mechanistic, etc.), descriptive and/or quantitative definitions of BPD to be used as comparators for a future definition.

[16] Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy

• Authors: L. Velicki, D. Jakovljevic, A. Preveden, M. Golubovic, M. Bjelobrk et al.
• Year: 2020
• Venue: BMC Cardiovascular Disorders
• URL: https://www.semanticscholar.org/paper/5b4558af699aad557a802ddc5c280ae601c2d56f
• DOI: 10.1186/s12872-020-01807-4
• PMID: 33297970
• PMCID: 7727200
• Citations: 55
• Influential citations: 2
• Summary: Major findings of the present study corroborate the notion that MYH7 gene mutation patients are presented with more pronounced disease severity than those with MYBPC3.
• Evidence snippets:
• Snippet 1 (score: 0.356) > ]. Technological progress has made it possible to identify new genes associated with HCM-numerous other genes that do not encode sarcomere proteins but rather genes encoding the synthesis of Z-disk proteins and proteins involved in the calcium signaling pathway. With the introduction and implementation of the next-generation sequencing solutions, the identification of nearly 50 gene mutations associated with some form of HCM throughout literature has become possible [12]. > Regardless of the mutation type, the same pathophysiology mechanisms are responsible for the development of typical HCM phenotype and disease progression. Disrupted sarcomere properties due to the mutations cause impaired relaxation and lead to diastolic dysfunction, which is followed by hyperdynamic contractility and hypertrophy of the LV in the later course [9,11]. > Due to variable penetrance and expressivity, the phenotypic characteristics of HCM are multifaceted and may be influenced by other factors beyond single pathogenic mutations [13]. In addition to LV hypertrophy, phenotypic HCM expression also includes myocardial hypercontractivity, myofibril disorganization, fibrosis, as well as the presence of mild myocardial inflammation. Although the clinical phenotype can partially differ depending on the affected gene, no distinctive correlation between disease severity and specific genes has been established. Moreover, clinical features such as disease penetration, hypertrophy severity, and patient prognosis are known to vary depending on different mutations within the same gene [11]. > The precise link between determined underlying gene mutation and the clinical course remains elusive in this heterogeneous condition. The motivation to compile this HCM patient registry was to try to define what patient features are more prevalent with specific gene mutations and to establish whether the level of disease expression might be linked to one of the two most common mutations responsible for HCM. The goal was to reveal and distinguish subtle differences that may exist in clinical presentation and, more importantly, in heart structure and function recorded by cardiac imaging (i.e. echocardiography) between different gene mutations, thus providing essential information for the computational model development. Moreover, data from this study will also complement the clinical trial (NCT03832660 at clinicaltrials.gov) evaluating the effects of pharmacological (sacub

[17] 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases

• Authors: E. Nemutlu, Song Zhang, N. Juranic, A. Terzic, S. Macura et al.
• Year: 2012
• Venue: Croatian Medical Journal
• URL: https://www.semanticscholar.org/paper/880f053c7f060db4b990e447d0a22c4b69372ddb
• DOI: 10.3325/cmj.2012.53.529
• PMID: 23275318
• PMCID: 3541579
• Citations: 28
• Summary: The potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic is described and discussed briefly.
• Evidence snippets:
• Snippet 1 (score: 0.356) > Living cells represent an integrated and interacting network of genes, transcripts, proteins, small signaling molecules, and metabolites that define cellular phenotype and function. Traditionally the focus of biomedical research was on individual genes, single protein targets, single metabolites, and metabolic or signaling pathways. This "molecular reductionist" paradigm was based on the assumption that identifying genetic variations and molecular components would lead to discovery of cures for human diseases. However, most of diseases are complex and multi-factorial and the disease phenotype is determined by the alterations of multiple genes, pathways, proteins and metabolites (at cellular, tissue, and organismal levels). Therefore, an integrated "omics" approach is more viable direction for uncovering alterations in metabolic networks, disease mechanisms, and mechanisms of drug effects. > Recent advent of large-scale metabolomics and fluxomic (metabolite dynamics and metabolic flux analysis) completed the "omics revolution" (Figure 1), where genomics, transcriptomics, proteomics, metabolomics, and fluxomics all together complement phenotype determination of living organism. Such integrated "omics" cascades provide a framework for advances in system and network biology, integrative physiology, and system medicine as well as system pharmacology and regenerative medicine. Noteworthy is the "reverse omic" approach or "metabolomicsinformed pharmacogenomics, " where discovery of specific metabolite changes have led to discovery of genetic alterations (2). Therefore, bringing new "omics" technologies to clinical practice will improve disease diagnostics and treatment by targeting drugs and procedures for each unique transcriptomic and metabolomic profiles.

[18] Knee Osteoarthritis—How Close Are We to Disease-Modifying Treatment: Emphasis on Metabolic Type Knee Osteoarthritis

• Authors: S. Lambova
• Year: 2023
• Venue: Life
• URL: https://www.semanticscholar.org/paper/40481a4f18e0f7795a5386b8c4b1711d9c98845f
• DOI: 10.3390/life13010140
• PMID: 36676089
• PMCID: 9866724
• Citations: 5
• Summary: Osteoarthritis (OA) is a whole-joint disease that affects cartilage, bone, and synovium as well as ligaments, menisci, and muscles [...].
• Evidence snippets:
• Snippet 1 (score: 0.355) > The heterogeneous nature of OA regarding localization and its dominant pathogenic mechanism are the major causes for unsatisfactory therapeutic results in relation to slowing of structural progression. The standard pharmacological treatments used in OA are nonsteroidal anti-inflammatory drugs, analgesics, and symptomatic, slow-acting agents with chondroprotective properties (e.g., glucosamine, chondroitin, soy and avocado, and intraarticular hyaluronic acid) [2,3]. > The knee is the most commonly affected joint in OA. The existence of different phenotypes of knee OA has been suggested; however, the precise criteria for their classification are not well-defined. While clinical phenotypes are characterized by common risk factors and can be used to determine progression and predict therapeutic response, the endotypes are disease subtypes characterized by well-defined molecular mechanisms, i.e., cellular and biochemical signaling pathways [4]. > Based on a systematic literature review, Dell'Isola et al. (2016) have proposed the existence of six phenotypes of knee OA related to predominant pathogenic mechanisms, i.e., a chronic pain phenotype, an inflammatory phenotype, phenotypes associated with alterations in bone and cartilage metabolism, with metabolic syndrome, a mechanical phenotype, and minimal joint disease. The chronic pain phenotype is thought to be related to central sensitization and alterations in pain neurophysiology and the psychological profile. Regarding the inflammatory type of knee OA, gene overexpression of inflammatory cytokines was detected, e.g., interleukin (IL)-1β, cyclooxygenase 2, and macrophage-inflammatory proteins. Higher level of pain and faster radiographic progression were observed in these cases compared to those with low cytokine expression. In the metabolic type of knee OA, it has been suggested that metabolic syndrome contributes to the development of knee OA, and this phenotype has been associated with higher levels of leptin and high-sensitivity CRP (hsCRP).

[19] Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies

• Authors: J. Casanova, M. Conley, S. Seligman, L. Abel, L. Notarangelo
• Year: 2014
• Venue: The Journal of Experimental Medicine
• URL: https://www.semanticscholar.org/paper/6f6b8309ebce06da91e67c72a535694969115597
• DOI: 10.1084/jem.20140520
• PMID: 25311508
• PMCID: 4203950
• Citations: 235
• Influential citations: 5
• Summary: The importance of single-patient genetic studies in the discovery of novel primary immunodeficiencies and insight into the standards and criteria that should accompany these studies are offered.
• Evidence snippets:
• Snippet 1 (score: 0.353) > a. A variant in a protein-coding gene can be nonsynonymous (change the amino acid sequence) or, if synonymous, have a proven impact on mRNA structure or amount (e.g., create an abnormal splicing site). A variant in an RNA gene must affect its function (if its expression is detectable). > b. Studies should document whether the variant changes the amount or molecular weight of the gene transcript and of the encoded protein. Ideally, this should be done in control primary cells or iPSC-derived cell lines, and not only in control immortalized cell lines. > c. Computer programs that predict whether a missense variant is damaging are helpful but not conclusive. A variation that is not conservative and that occurs in a region or at a residue of the encoded protein that is highly conserved in evolution provides support for the hypothesis that the amino acid is functionally important. > d. The variants must be loss or gain of function for at least one biological activity. For variants that result in an amino acid substitution, insertion, or deletion, in vitro studies should document a functional change that reveals the mechanism by which the variant causes disease. For example, the protein may be unstable, it may not bind essential cofactors, or it may not localize appropriately. > 3. The causal relationship between the candidate genotype and the clinical phenotype must be established via a relevant cellular or animal phenotype. > a. In all cases, the candidate gene should be known or shown to be normally expressed in cell types relevant to the disease process. These may be cells affected by the disease process, cells which produce factors needed by the affected cells or progenitors of the cell lineage affected by the disease. Some genes are broadly expressed but have a narrow clinical phenotype. > b. For disorders that affect the function of a cell (present in the patient), experimental studies in vitro must indicate that there is a cellular phenotype explained by the candidate genotype (see c). This cellular phenotype should reasonably account for the clinical phenotype because the cell type is known to be involved in the disease process and the clinical phenotype is consistent with it. For example, if the candidate gene can be connected to a known disease-causing gene via a common cellular phenotype (e.g., mutations

[20] Structural, cellular and molecular mechanisms involved in the Epithelial-to-Mesenchymal Transition in Cancer

• Authors: Moniri Javadhesari, Vaezi Heris
• Year: 2022
• Venue: Journal of Cell and Tissue
• URL: https://www.semanticscholar.org/paper/0e5acf2d67a761fb70d6a28a6f6f60fbe88abcf2
• DOI: 10.52547/jct.13.2.71
• Summary: EMT plays a crucial role in cancer progression, crossing the cells through the biological and body barriers, and metastasis that are usually associated with poor prognosis of cancer patients.
• Evidence snippets:
• Snippet 1 (score: 0.351) > Epithelial-Mesenchymal Transition, Carcinogenesis, Gene Expression Regulation, Tumor Microenvironment. Intoduction: Cancer as one of the most common genetic diseases is the leading cause of death worldwide. Cancer cells undergo various genetic and phenotypic changes to spread and survive. In the early stages, these changes lead to the development of tumor, while at the advanced stages they can provide a suitable pre-metastatic microenvironment in which various uncontrolled events occur including cell proliferation, traversing through the extracellular matrix, and crossing barriers to enter the bloodstream. Extracellular changes in this microenvironment can induce intracellular changes in primary cancer cells that assist in the sustainability and propagation of these cells. Complicated interactions between the external and internal factors result in the establishment of various regulatory networks between different types of carcinogenesis promoting factors. Identification of these modifications plays a critical role in understanding the mechanisms of disease progression, prognosis and management. Text: Various mutations and differential gene expression trigger metastasis of cancer cells by epithelial to mesenchymal transition (EMT) mechanism, among which the role of chromatin structural changes, intracellular signal transduction pathways, regulation of cell cycle and microRNAs, and genomic instability has been reported. The alterations in gene expression patterns of mentioned pathways lead to potential regulatory complications that faced the management of disease progression and response to therapies with problems. Cancer cells provide their requirements by neutralizing biological barriers, modifying the regulation of inhibiting processes of cancer progression, establishing de novo endogenous mechanisms and providing specialized molecular and structural markers, and various combinations of these methods have been demonstrated in different types of cancer. Furthermore, EMT and Structural, cellular and molecular mechanisms involved in the Epithelial-to-Mesenchymal Transition in Cancer Journal of Cell and Tissue 13(2) (2022) 71-94 cancer stem cells (CSCs) have a mutual relationship in which the presence of one assists the occurrence of the other. Altogether, cancer cells take the advantage of multiple approaches including upregulation of main transcription factors such as snail, slug, Foxc2, Twist and ZEB1/2, benefiting the mechanisms of telomere length protection, production of CD133,CD44 and BMI1 biomark

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Disorder

• Name: Hypochondrogenesis
• Category: Mendelian
• Existing deep-research providers: cyberian-codex, perplexity
• Existing evidence reference count in YAML: 16

Key Pathophysiology Nodes

• Type II Collagen Structural Defect
• Endoplasmic Reticulum Stress and Chondrocyte Apoptosis
• Deep research literature mapping

Citation Inventory (for evidence mapping)

• DOI:10.1002/humu.20603
• DOI:10.1002/uog.3461
• DOI:10.1177/875647930101700609
• DOI:10.3389/fbioe.2025.1740135
• PMID:25169886
• PMID:25187577
• PMID:2572591
• PMID:3057886
• PMID:3717210
• PMID:6641761
• PMID:8175802
• PMID:8346704

Hypochondrogenesis (COL2A1-related type II collagenopathy): Pathophysiology Research Report

Disease overview and definitions

Hypochondrogenesis is a severe, usually perinatal-lethal skeletal dysplasia within the type II collagenopathy spectrum caused by pathogenic variants in COL2A1 (type II procollagen). It overlaps clinically and mechanistically with achondrogenesis type II, and both are often discussed as a continuum of severity within COL2A1 structural (dominant-negative) disease. (wu2025prenatalimagingof pages 6-7, myllyharju2014extracellularmatrixand pages 1-2)

Key concept (current understanding): hypochondrogenesis is best understood as a combined disorder of (i) intracellular procollagen II proteostasis (misfolding, delayed folding, intracellular retention, ER stress/UPR signaling and/or proteostasis failure) and (ii) extracellular matrix (ECM) insufficiency/architectural disruption of collagen II fibrils, which secondarily derails growth plate organization and endochondral ossification. (okada2015modelingtypeii pages 2-4, lamande2023modelinghumanskeletal pages 7-9, lamande2023modelinghumanskeletal pages 5-6)

Note on MONDO: A MONDO identifier was not available in the retrieved sources.

1) Core pathophysiology

1.1 Primary mechanisms

A. Collagen II misfolding and intracellular retention

A common pathogenic class in COL2A1 disorders is glycine substitution in the triple-helical Gly–X–Y repeats, which disrupts helix stability and/or folding and can cause intracellular accumulation rather than secretion. Patient-derived cellular studies show marked intracellular collagen II accumulation with absent extracellular collagen II deposition, consistent with a secretion/trafficking failure driven by mutant procollagen. (marchionni2023clinicalandfunctional pages 3-4)

A major 2023 human stem-cell cartilage model directly demonstrates this mechanism in a hypochondrogenesis mutation context: iPSC-derived chondronoids carrying COL2A1 p.G1113C (heterozygous) show reduced collagen II ECM with prominent intracellular collagen II aggregates. (lamande2023modelinghumanskeletal pages 7-9, lamande2023modelinghumanskeletal pages 5-6, lamande2023modelinghumanskeletal media 5b868ad2)

B. ER stress and unfolded protein response (UPR) engagement (variable across alleles)

Misfolded collagens can elicit ER stress and activate the three canonical UPR sensors PERK, IRE1, and ATF6, which initially attempt proteostatic recovery but can transition to apoptosis under chronic unresolved stress (e.g., via ATF4→CHOP/DDIT3 and IRE1-linked pro-apoptotic signaling). (bateman2022collagenmisfoldingmutations pages 2-4)

For COL2A1/collagen II misfolding mutations, reported UPR-related signatures include upregulation of BiP/GRP94, CHOP, eIF2α phosphorylation (PERK arm), ATF6 induction/activation, and XBP1 splicing (IRE1 arm), with apoptosis reported in severe contexts; however, the extent of canonical UPR activation can vary by allele and zygosity. (bateman2022collagenmisfoldingmutations pages 11-12)

A complementary review focused on cartilage pathophysiology notes that intracellular retention of misfolded mutant COL2A1 in a mouse model is associated with distended rough ER and UPR signaling early in life, linking collagen II retention to ER stress mechanisms in chondrocytes. (hughes2017endoplasmicreticulumstress pages 3-5)

C. ECM fibril deficiency and disorganization

Even when some mutant collagen is secreted, collagen II can be insufficient or structurally abnormal, leading to sparse, disorganized fibrils and compromised cartilage matrix integrity. In the 2023 iPSC hypochondrogenesis model, TEM shows reduced/disorganized collagen II fibrils in mutant cartilage. (lamande2023modelinghumanskeletal pages 7-9, lamande2023modelinghumanskeletal pages 5-6, lamande2023modelinghumanskeletal media 5b868ad2)

Patient-cell functional work similarly indicates broader ECM disruption: collagen II trafficking/assembly defects were accompanied by a disorganized fibronectin network, implying downstream ECM architectural consequences beyond collagen itself. (marchionni2023clinicalandfunctional pages 3-4)

1.2 Dysregulated molecular pathways and affected cellular processes

Key dysregulated processes supported by the retrieved evidence include:

• Protein folding/proteostasis in the secretory pathway (ER quality control, trafficking, degradation), with potential activation of UPR signaling branches. (bateman2022collagenmisfoldingmutations pages 2-4, bateman2022collagenmisfoldingmutations pages 11-12)
• Collagen biosynthesis, post-translational processing, secretion, and fibril assembly, leading to reduced functional collagen II in cartilage ECM. (marchionni2023clinicalandfunctional pages 3-4, lamande2023modelinghumanskeletal pages 7-9)
• Chondrocyte differentiation and survival (apoptosis in severe models; impaired chondrogenic differentiation in patient-derived cell studies). (okada2015modelingtypeii pages 2-4, marchionni2023clinicalandfunctional pages 3-4)
• Growth plate cartilage organization and endochondral ossification, as an emergent tissue-level failure when cartilage ECM is inadequate and/or chondrocytes are stressed/dysfunctional. (myllyharju2014extracellularmatrixand pages 1-2, okada2015modelingtypeii pages 2-4)

2) Key molecular players

2.1 Genes/proteins

• COL2A1 (HGNC:2200): causal gene encoding type II procollagen (principal cartilage fibrillar collagen). Functional studies support that glycine substitutions can drive intracellular retention and secretion failure. (marchionni2023clinicalandfunctional pages 1-2, marchionni2023clinicalandfunctional pages 3-4, lamande2023modelinghumanskeletal pages 7-9)

• UPR mediators (pathway-level): PERK/EIF2AK3 → eIF2α phosphorylation → ATF4 → CHOP/DDIT3; IRE1/ERN1 → XBP1 splicing; ATF6 activation. These are mechanistically linked to proteostasis outcomes and apoptosis under unresolved ER stress in collagenopathies, including collagen II contexts where UPR markers have been observed. (bateman2022collagenmisfoldingmutations pages 2-4, bateman2022collagenmisfoldingmutations pages 11-12)

2.2 Chemical entities (metabolites/drugs/small molecules)

Evidence from COL2A1 disease modeling and ER-stress literature highlights several chemicals relevant to mechanism and experimental intervention:

• Trimethylamine N-oxide (TMAO) (chemical chaperone): In a COL2A1/type II collagenopathy iChon model, TMAO increased extracellular type II collagen and partially decreased apoptosis, consistent with proteostasis improvement; it also reduced an ER-stress marker (BiP) in the model. (okada2015modelingtypeii pages 10-12, okada2015modelingtypeii pages 17-18)

• 4-phenylbutyric acid (4-PBA) (chemical chaperone/ER-stress modulator): Reported to reduce ER stress in chondrocyte ER-stress contexts and discussed as a potential therapeutic avenue for ER stress diseases involving type II collagen retention, though in vivo efficacy may vary by disease/model. (briggs2020newdevelopmentsin pages 5-6)

• ISRIB (integrated stress response inhibitor): Demonstrated to restore bone growth and suppress ATF4/CHOP translation in an ER-stress chondrodysplasia model (not COL2A1-specific), supporting feasibility of targeting translation/ISR pathways relevant to UPR-mediated pathology. (briggs2020newdevelopmentsin pages 5-6)

• Ascorbic acid (vitamin C): In COL2A1 mutant iChon cells, ascorbic acid increased multiple ER-stress markers (BiP/GRP94/CHOP; phospho-eIF2α; cleaved ATF6) and reduced chondrogenic nodules, suggesting that forcing collagen biosynthesis/processing can worsen proteostatic load in some mutant contexts. (okada2015modelingtypeii pages 9-10)

• Bafilomycin A1 and MG132: Used experimentally to probe degradation routes; bafilomycin A1 increased type II collagen levels in the iChon model, implicating lysosomal contribution to collagen clearance, whereas MG132 did not show the same effect in the described assay. (okada2015modelingtypeii pages 10-12)

2.3 Cell types

• Chondrocytes (CL:0000138) are the primary affected cell type; they are professional secretory cells, making them vulnerable to proteostasis disruption when ECM proteins misfold or accumulate. (briggs2020newdevelopmentsin pages 1-3)

2.4 Anatomical locations/tissues

• Cartilage ECM and growth plate cartilage (UBERON:0002384 cartilage; UBERON:0005868 growth plate cartilage) are principal sites of pathology, consistent with type II collagen’s dominant role in cartilage structure and endochondral ossification. (myllyharju2014extracellularmatrixand pages 1-2, lamande2023modelinghumanskeletal pages 5-6)

3) Biological processes (GO-oriented) disrupted (candidate GO annotations)

Based on the evidence, hypochondrogenesis can be annotated to disruption of:

• Collagen fibril organization (GO:0030199) and collagen biosynthetic process (GO:0032964), reflecting impaired production/assembly of collagen II fibrils. (lamande2023modelinghumanskeletal pages 7-9, marchionni2023clinicalandfunctional pages 3-4)
• Protein folding (GO:0006457), response to ER stress (GO:0034976), and response to unfolded protein (GO:0006986), reflecting intracellular retention/misfolding and UPR involvement. (bateman2022collagenmisfoldingmutations pages 2-4, bateman2022collagenmisfoldingmutations pages 11-12)
• Apoptotic signaling pathway (GO:0097190) in severe misfolding/ER stress contexts. (bateman2022collagenmisfoldingmutations pages 2-4, okada2015modelingtypeii pages 2-4)
• Endochondral ossification (GO:0001958) and skeletal system development (GO:0001501), reflecting downstream growth plate dysfunction. (myllyharju2014extracellularmatrixand pages 1-2, okada2015modelingtypeii pages 2-4)

4) Cellular components (GO CC) implicated

Key cellular compartments implicated by mechanistic evidence include:

• Rough endoplasmic reticulum (GO:0005791): site of procollagen folding/retention, ER distension, and UPR signaling. (hughes2017endoplasmicreticulumstress pages 3-5, okada2015modelingtypeii pages 2-4)
• Golgi apparatus (GO:0005794) / Golgi vesicular structures: patient-derived cellular evidence localizes accumulated collagen II to Golgi-associated vesicles in a COL2A1 glycine-substitution context, consistent with trafficking disruption. (marchionni2023clinicalandfunctional pages 3-4)
• Collagen-containing extracellular matrix (GO:0062023) / extracellular matrix (GO:0031012): site of collagen II fibril insufficiency and disorganization. (lamande2023modelinghumanskeletal pages 7-9, lamande2023modelinghumanskeletal pages 5-6)

5) Disease progression (sequence of events)

A mechanistically supported disease sequence is:

1. Initiating trigger: heterozygous COL2A1 structural variant (often triple-helix glycine substitution) generates mutant procollagen II. (marchionni2023clinicalandfunctional pages 1-2, wu2025prenatalimagingof pages 6-7)
2. Intracellular proteostasis defect: delayed folding/misfolding causes intracellular accumulation/retention in the secretory pathway (ER and/or Golgi-associated compartments), with potential activation of ER stress/UPR signaling in some alleles. (marchionni2023clinicalandfunctional pages 3-4, bateman2022collagenmisfoldingmutations pages 11-12)
3. ECM deficiency: reduced secretion and/or secretion of dysfunctional collagen II yields a sparse/disorganized collagen II matrix. (lamande2023modelinghumanskeletal pages 7-9, lamande2023modelinghumanskeletal media 5b868ad2)
4. Cell and tissue dysfunction: impaired chondrocyte differentiation and/or apoptosis and disorganized cartilage architecture disrupt growth plate function and endochondral ossification. (okada2015modelingtypeii pages 2-4, myllyharju2014extracellularmatrixand pages 1-2)
5. Clinical manifestation: severe skeletal dysplasia phenotype consistent with hypochondrogenesis/achondrogenesis spectrum (short limbs, vertebral and thoracic abnormalities, perinatal lethality in the severe end). (wu2025prenatalimagingof pages 6-7, myllyharju2014extracellularmatrixand pages 1-2)

6) Phenotypic manifestations and mechanistic links (HPO-oriented)

Representative phenotypes (illustrative HPO terms) include:

• Short limbs (e.g., HP:0002117) and severe short stature due to growth plate failure and impaired endochondral ossification. (myllyharju2014extracellularmatrixand pages 1-2, wu2025prenatalimagingof pages 6-7)
• Platyspondyly (HP:0000926) and vertebral anomalies due to abnormal cartilage templates and ECM defects. (wu2025prenatalimagingof pages 6-7)
• Perinatal lethality in severe COL2A1 continuum phenotypes (often via thoracic insufficiency/respiratory failure). (wu2025prenatalimagingof pages 6-7, myllyharju2014extracellularmatrixand pages 1-2)

Recent developments and latest research (prioritizing 2023–2024)

2023: Human iPSC-derived developmental skeletal model directly modeling hypochondrogenesis

Lamandé et al. (PNAS, publication date May 2023) present a human iPSC-based platform that recapitulates cartilage maturation and mineralizing transitions and demonstrate disease modeling for hypochondrogenesis using a COL2A1 p.G1113C line. A key quantitative finding is a large increase in chondrocytes with intracellular collagen II aggregates (58% mutant vs 7% control) alongside reduced collagen II ECM and sparse/disorganized fibrils (Figure 4A–B). This represents a high-value, human genotype-accurate experimental system for mechanistic studies and therapeutic screening. URL: https://doi.org/10.1073/pnas.2211510120 (lamande2023modelinghumanskeletal pages 7-9, lamande2023modelinghumanskeletal pages 5-6, lamande2023modelinghumanskeletal media 5b868ad2)

2023: Functional characterization of COL2A1 variant with cellular ECM readouts

Marchionni et al. (Bone Reports, publication date Dec 2023) provide patient-cell mechanistic evidence for a COL2A1 glycine substitution (p.Gly444Ser), reporting impaired chondrogenic differentiation, intracellular collagen II accumulation, lack of extracellular collagen II deposition, and ECM disorganization (fibronectin network). URL: https://doi.org/10.1016/j.bonr.2023.101728 (marchionni2023clinicalandfunctional pages 3-4)

2024: Real-world gene panel implementation and outcomes in skeletal dysplasia

MacCarrick et al. (Am J Med Genet A, publication date May 2024) report the largest cohort to date (n=5,011; Dec 2019–Apr 2022 testing window) evaluating multigene panel testing for skeletal dysplasia. The study’s diagnostic yield was 27.4%, with care/treatment implications for 84.4% of positive diagnoses, supporting broad deployment of molecular diagnostics in skeletal dysplasia workflows—including COL2A1 phenotypes that are difficult to resolve clinically given overlap across multiple disorders. URL: https://doi.org/10.1002/ajmg.a.63646 (maccarrick2024clinicalutilityof pages 1-2, maccarrick2024clinicalutilityof pages 2-3)

2024: Updated nosology and disease-group scale

A 2024 clinical overview of skeletal dysplasias highlights that the 2023 Nosology includes 771 entries, caused by variants in 552 genes, organized into 41 groups, emphasizing rapid expansion of genotype–phenotype mapping relevant to cartilage disorders. URL: https://doi.org/10.12956/tchd.1380641 (dasar2024overviewofskeletal pages 1-2)

Current applications and real-world implementations

Molecular diagnosis (panels, exome, and assay design)

• Gene panels: Large-cohort evidence indicates panels are widely used and yield clinically actionable results for a substantial fraction of suspected skeletal dysplasia cases (27.4% overall yield in 5,011 individuals). (maccarrick2024clinicalutilityof pages 1-2)
• Handling large, multi-exon collagen genes: Long-range PCR-based NGS (vLAS) is proposed to streamline analysis of large collagen genes such as COL2A1 (54 exons; ~31.5 kb), covering entire genes with ~20 kb amplicons, supporting practical clinical implementation alternatives to exon-by-exon Sanger sequencing or capture-probe design. URL: https://doi.org/10.7759/cureus.50482 (niida2023streamlininggeneticdiagnosis pages 1-2)

Prenatal evaluation

Although detailed prenatal-pathway statistics were limited in the retrieved 2023–2024 texts, current practice referenced in skeletal dysplasia genetic testing literature includes prenatal ultrasound suspicion followed by molecular testing (gene panels or exome) to distinguish overlapping lethal/nonlethal skeletal dysplasias. (maccarrick2024clinicalutilityof pages 2-3)

Expert opinions and analysis (authoritative sources)

• Expert reviews emphasize that ER stress/UPR is a plausible, druggable mechanism in genetic cartilage diseases, but that the strength of evidence for canonical, cytotoxic UPR varies between collagen types and mutations; they argue that mechanistic studies must be performed in the relevant target cells (chondrocytes) and allele contexts. (bateman2022collagenmisfoldingmutations pages 2-4, bateman2022collagenmisfoldingmutations pages 11-12)

• Reviews focusing on cartilage ER stress describe chondrocyte ER stress as a core disease mechanism in subsets of genetic skeletal diseases and highlight experimental modulation by chemical chaperones and ISR inhibitors as emerging therapeutic strategies. (briggs2020newdevelopmentsin pages 1-3, briggs2020newdevelopmentsin pages 5-6)

Relevant statistics and data (recent)

• Skeletal dysplasia birth incidence (collective): approximately 1 in 5,000 live births; alternatively 2.4–4.5 per 10,000 live births, estimated as ~5% of all birth defects (review-level epidemiology). (dasar2024overviewofskeletal pages 1-2)
• Genetic nosology scale: 2023 revision includes 771 entries, 552 genes, 41 groups. (dasar2024overviewofskeletal pages 1-2)
• Diagnostic yield (real-world U.S. panel testing): 27.4% molecular diagnostic yield among 5,011 individuals; 84.4% of molecular diagnoses had implications for specific care/treatment decisions. (maccarrick2024clinicalutilityof pages 1-2)
• Quantitative cellular pathology in a 2023 hypochondrogenesis model: intracellular collagen II aggregates in 58% of mutant chondrocytes vs 7% in isogenic control. (lamande2023modelinghumanskeletal pages 7-9, lamande2023modelinghumanskeletal media 5b868ad2)

Evidence-backed mechanistic summary table

The following table consolidates mechanism-to-ontology mappings and key evidence items.

Table: This table maps the main molecular, cellular, and tissue-level mechanisms implicated in hypochondrogenesis, centered on COL2A1 dysfunction. It also highlights recent disease-model evidence, including 2023 iPSC/organoid findings and clinically relevant diagnostic applications.

Key evidence item (visual)

Figure evidence from the 2023 iPSC hypochondrogenesis model (COL2A1 p.G1113C) shows reduced collagen II ECM, intracellular collagen II aggregates (with quantification), and TEM evidence of sparse/disorganized fibrils. (lamande2023modelinghumanskeletal media 5b868ad2)

Evidence items list (PMIDs where available)

The retrieved full-text excerpts did not consistently include PMIDs; therefore, PMIDs cannot be reliably provided without additional database lookups. The following evidence items (with DOI URLs and publication timing) support the mechanistic claims above:

• Lamandé SR et al. PNAS (May 2023): https://doi.org/10.1073/pnas.2211510120 (lamande2023modelinghumanskeletal pages 7-9, lamande2023modelinghumanskeletal pages 5-6, lamande2023modelinghumanskeletal media 5b868ad2)
• Marchionni E et al. Bone Reports (Dec 2023): https://doi.org/10.1016/j.bonr.2023.101728 (marchionni2023clinicalandfunctional pages 1-2, marchionni2023clinicalandfunctional pages 3-4)
• MacCarrick G et al. Am J Med Genet A (May 2024): https://doi.org/10.1002/ajmg.a.63646 (maccarrick2024clinicalutilityof pages 1-2, maccarrick2024clinicalutilityof pages 2-3)
• Niida Y et al. Cureus (Dec 2023): https://doi.org/10.7759/cureus.50482 (niida2023streamlininggeneticdiagnosis pages 1-2)
• Bateman JF et al. Connective Tissue Research (Feb 2022): https://doi.org/10.1080/03008207.2022.2036735 (bateman2022collagenmisfoldingmutations pages 2-4, bateman2022collagenmisfoldingmutations pages 11-12)
• Briggs MD et al. F1000Research (Apr 2020): https://doi.org/10.12688/f1000research.22275.1 (briggs2020newdevelopmentsin pages 1-3, briggs2020newdevelopmentsin pages 5-6)
• Okada M et al. Human Molecular Genetics (Jan 2015): https://doi.org/10.1093/hmg/ddu444 (okada2015modelingtypeii pages 2-4, okada2015modelingtypeii pages 10-12)
• Myllyharju J. Current Osteoporosis Reports (Sep 2014): https://doi.org/10.1007/s11914-014-0232-1 (myllyharju2014extracellularmatrixand pages 1-2)

References

1. (wu2025prenatalimagingof pages 6-7): Yi-Cheng Wu, Chih-Yao Chen, Guan-Yeu Chen, Ching-Hua Hsiao, Woei-Chyn Chu, and Jack Yu-Jen Huang. Prenatal imaging of micrognathia, micromelia, and fetal hydrops leading to the diagnosis of achondrogenesis type ii with a col2a1 missense mutation. International Journal of Molecular Sciences, 26:11472, Nov 2025. URL: https://doi.org/10.3390/ijms262311472, doi:10.3390/ijms262311472. This article has 0 citations.

2. (myllyharju2014extracellularmatrixand pages 1-2): Johanna Myllyharju. Extracellular matrix and developing growth plate. Current Osteoporosis Reports, 12:439-445, Sep 2014. URL: https://doi.org/10.1007/s11914-014-0232-1, doi:10.1007/s11914-014-0232-1. This article has 59 citations and is from a peer-reviewed journal.

3. (okada2015modelingtypeii pages 2-4): Minoru Okada, Shiro Ikegawa, Miho Morioka, Akihiro Yamashita, Atsushi Saito, Hideaki Sawai, Jun Murotsuki, Hirofumi Ohashi, Toshio Okamoto, Gen Nishimura, Kazunori Imaizumi, and Noriyuki Tsumaki. Modeling type ii collagenopathy skeletal dysplasia by directed conversion and induced pluripotent stem cells. Human molecular genetics, 24 2:299-313, Jan 2015. URL: https://doi.org/10.1093/hmg/ddu444, doi:10.1093/hmg/ddu444. This article has 49 citations and is from a domain leading peer-reviewed journal.

4. (lamande2023modelinghumanskeletal pages 7-9): Shireen R. Lamandé, Elizabeth S. Ng, Trevor L. Cameron, Louise H. W. Kung, Lisa Sampurno, Lynn Rowley, Jinia Lilianty, Yudha Nur Patria, Tayla Stenta, Eric Hanssen, Katrina M. Bell, Ritika Saxena, Kathryn S. Stok, Edouard G. Stanley, Andrew G. Elefanty, and John F. Bateman. Modeling human skeletal development using human pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, May 2023. URL: https://doi.org/10.1073/pnas.2211510120, doi:10.1073/pnas.2211510120. This article has 72 citations and is from a highest quality peer-reviewed journal.

5. (lamande2023modelinghumanskeletal pages 5-6): Shireen R. Lamandé, Elizabeth S. Ng, Trevor L. Cameron, Louise H. W. Kung, Lisa Sampurno, Lynn Rowley, Jinia Lilianty, Yudha Nur Patria, Tayla Stenta, Eric Hanssen, Katrina M. Bell, Ritika Saxena, Kathryn S. Stok, Edouard G. Stanley, Andrew G. Elefanty, and John F. Bateman. Modeling human skeletal development using human pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, May 2023. URL: https://doi.org/10.1073/pnas.2211510120, doi:10.1073/pnas.2211510120. This article has 72 citations and is from a highest quality peer-reviewed journal.

6. (marchionni2023clinicalandfunctional pages 3-4): Enrica Marchionni, Maria Rosaria D'Apice, Viviana Lupo, Giovanna Lattanzi, Elisabetta Mattioli, Gina Lisignoli, Elena Gabusi, Gerardo Pepe, Manuela Helmer Citterich, Elena Campione, Anna Maria Nardone, Paola Spitalieri, Noemi Pucci, Dario Cocciadiferro, Eliseo Picchi, Francesco Garaci, Antonio Novelli, and Giuseppe Novelli. Clinical and functional characterization of col2a1 p.gly444ser variant: from a fetal phenotype to a previously undisclosed postnatal phenotype. Bone Reports, 19:101728, Dec 2023. URL: https://doi.org/10.1016/j.bonr.2023.101728, doi:10.1016/j.bonr.2023.101728. This article has 1 citations and is from a peer-reviewed journal.

7. (lamande2023modelinghumanskeletal media 5b868ad2): Shireen R. Lamandé, Elizabeth S. Ng, Trevor L. Cameron, Louise H. W. Kung, Lisa Sampurno, Lynn Rowley, Jinia Lilianty, Yudha Nur Patria, Tayla Stenta, Eric Hanssen, Katrina M. Bell, Ritika Saxena, Kathryn S. Stok, Edouard G. Stanley, Andrew G. Elefanty, and John F. Bateman. Modeling human skeletal development using human pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, May 2023. URL: https://doi.org/10.1073/pnas.2211510120, doi:10.1073/pnas.2211510120. This article has 72 citations and is from a highest quality peer-reviewed journal.

8. (bateman2022collagenmisfoldingmutations pages 2-4): John F. Bateman, Matthew D. Shoulders, and Shireen R. Lamandé. Collagen misfolding mutations: the contribution of the unfolded protein response to the molecular pathology. Connective Tissue Research, 63:210-227, Feb 2022. URL: https://doi.org/10.1080/03008207.2022.2036735, doi:10.1080/03008207.2022.2036735. This article has 32 citations and is from a peer-reviewed journal.

9. (bateman2022collagenmisfoldingmutations pages 11-12): John F. Bateman, Matthew D. Shoulders, and Shireen R. Lamandé. Collagen misfolding mutations: the contribution of the unfolded protein response to the molecular pathology. Connective Tissue Research, 63:210-227, Feb 2022. URL: https://doi.org/10.1080/03008207.2022.2036735, doi:10.1080/03008207.2022.2036735. This article has 32 citations and is from a peer-reviewed journal.

10. (hughes2017endoplasmicreticulumstress pages 3-5): Alexandria Hughes, Alexandra Oxford, Ken Tawara, Cheryl Jorcyk, and Julia Oxford. Endoplasmic reticulum stress and unfolded protein response in cartilage pathophysiology; contributing factors to apoptosis and osteoarthritis. International Journal of Molecular Sciences, 18:665, Mar 2017. URL: https://doi.org/10.3390/ijms18030665, doi:10.3390/ijms18030665. This article has 118 citations.

11. (marchionni2023clinicalandfunctional pages 1-2): Enrica Marchionni, Maria Rosaria D'Apice, Viviana Lupo, Giovanna Lattanzi, Elisabetta Mattioli, Gina Lisignoli, Elena Gabusi, Gerardo Pepe, Manuela Helmer Citterich, Elena Campione, Anna Maria Nardone, Paola Spitalieri, Noemi Pucci, Dario Cocciadiferro, Eliseo Picchi, Francesco Garaci, Antonio Novelli, and Giuseppe Novelli. Clinical and functional characterization of col2a1 p.gly444ser variant: from a fetal phenotype to a previously undisclosed postnatal phenotype. Bone Reports, 19:101728, Dec 2023. URL: https://doi.org/10.1016/j.bonr.2023.101728, doi:10.1016/j.bonr.2023.101728. This article has 1 citations and is from a peer-reviewed journal.

12. (okada2015modelingtypeii pages 10-12): Minoru Okada, Shiro Ikegawa, Miho Morioka, Akihiro Yamashita, Atsushi Saito, Hideaki Sawai, Jun Murotsuki, Hirofumi Ohashi, Toshio Okamoto, Gen Nishimura, Kazunori Imaizumi, and Noriyuki Tsumaki. Modeling type ii collagenopathy skeletal dysplasia by directed conversion and induced pluripotent stem cells. Human molecular genetics, 24 2:299-313, Jan 2015. URL: https://doi.org/10.1093/hmg/ddu444, doi:10.1093/hmg/ddu444. This article has 49 citations and is from a domain leading peer-reviewed journal.

13. (okada2015modelingtypeii pages 17-18): Minoru Okada, Shiro Ikegawa, Miho Morioka, Akihiro Yamashita, Atsushi Saito, Hideaki Sawai, Jun Murotsuki, Hirofumi Ohashi, Toshio Okamoto, Gen Nishimura, Kazunori Imaizumi, and Noriyuki Tsumaki. Modeling type ii collagenopathy skeletal dysplasia by directed conversion and induced pluripotent stem cells. Human molecular genetics, 24 2:299-313, Jan 2015. URL: https://doi.org/10.1093/hmg/ddu444, doi:10.1093/hmg/ddu444. This article has 49 citations and is from a domain leading peer-reviewed journal.

14. (briggs2020newdevelopmentsin pages 5-6): Michael D. Briggs, Ella P. Dennis, Helen F. Dietmar, and Katarzyna A. Pirog. New developments in chondrocyte er stress and related diseases. F1000Research, 9:290, Apr 2020. URL: https://doi.org/10.12688/f1000research.22275.1, doi:10.12688/f1000research.22275.1. This article has 36 citations and is from a peer-reviewed journal.

15. (okada2015modelingtypeii pages 9-10): Minoru Okada, Shiro Ikegawa, Miho Morioka, Akihiro Yamashita, Atsushi Saito, Hideaki Sawai, Jun Murotsuki, Hirofumi Ohashi, Toshio Okamoto, Gen Nishimura, Kazunori Imaizumi, and Noriyuki Tsumaki. Modeling type ii collagenopathy skeletal dysplasia by directed conversion and induced pluripotent stem cells. Human molecular genetics, 24 2:299-313, Jan 2015. URL: https://doi.org/10.1093/hmg/ddu444, doi:10.1093/hmg/ddu444. This article has 49 citations and is from a domain leading peer-reviewed journal.

16. (briggs2020newdevelopmentsin pages 1-3): Michael D. Briggs, Ella P. Dennis, Helen F. Dietmar, and Katarzyna A. Pirog. New developments in chondrocyte er stress and related diseases. F1000Research, 9:290, Apr 2020. URL: https://doi.org/10.12688/f1000research.22275.1, doi:10.12688/f1000research.22275.1. This article has 36 citations and is from a peer-reviewed journal.

17. (maccarrick2024clinicalutilityof pages 1-2): Gretchen MacCarrick, Swaroop Aradhya, Mitch Bailey, Dorna Chu, Abigail Hunt, Emanuela Izzo, Deborah Krakow, William Mackenzie, Sarah Poll, Cathleen Raggio, Renée Shediac, Klane K. White, Heather M. McLaughlin, and Guillermo Seratti. Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: results from the largest cohort to date. American Journal of Medical Genetics Part A, May 2024. URL: https://doi.org/10.1002/ajmg.a.63646, doi:10.1002/ajmg.a.63646. This article has 3 citations.

18. (maccarrick2024clinicalutilityof pages 2-3): Gretchen MacCarrick, Swaroop Aradhya, Mitch Bailey, Dorna Chu, Abigail Hunt, Emanuela Izzo, Deborah Krakow, William Mackenzie, Sarah Poll, Cathleen Raggio, Renée Shediac, Klane K. White, Heather M. McLaughlin, and Guillermo Seratti. Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: results from the largest cohort to date. American Journal of Medical Genetics Part A, May 2024. URL: https://doi.org/10.1002/ajmg.a.63646, doi:10.1002/ajmg.a.63646. This article has 3 citations.

19. (dasar2024overviewofskeletal pages 1-2): Tuğba DAŞAR and Esra KILIÇ. Overview of skeletal dysplasias. Turkish Journal of Pediatric Disease, pages 1-11, Jan 2024. URL: https://doi.org/10.12956/tchd.1380641, doi:10.12956/tchd.1380641. This article has 1 citations.

20. (niida2023streamlininggeneticdiagnosis pages 1-2): Yo Niida, Sumihito Togi, and Hiroki Ura. Streamlining genetic diagnosis with long-range polymerase chain reaction (pcr)-based next-generation sequencing for type i and type ii collagenopathies. Cureus, Dec 2023. URL: https://doi.org/10.7759/cureus.50482, doi:10.7759/cureus.50482. This article has 3 citations.

21. (aljuid2026col2a1mutationsand pages 8-9): Latifa Mohammed Aljuid, Dareen Alyousfi, Manal Hosawi, and Ayman Z Elsamanoudy. Col2a1 mutations and type ii collagenopathies: molecular mechanisms and ipsc-based modeling of cartilage disorders. Archives of Stem Cell and Therapy, 6:6, Feb 2026. URL: https://doi.org/10.46439/stemcell.6.026, doi:10.46439/stemcell.6.026. This article has 0 citations.

22. (bateman2022collagenmisfoldingmutations pages 1-2): John F. Bateman, Matthew D. Shoulders, and Shireen R. Lamandé. Collagen misfolding mutations: the contribution of the unfolded protein response to the molecular pathology. Connective Tissue Research, 63:210-227, Feb 2022. URL: https://doi.org/10.1080/03008207.2022.2036735, doi:10.1080/03008207.2022.2036735. This article has 32 citations and is from a peer-reviewed journal.

23. (aljuid2026col2a1mutationsand pages 6-7): Latifa Mohammed Aljuid, Dareen Alyousfi, Manal Hosawi, and Ayman Z Elsamanoudy. Col2a1 mutations and type ii collagenopathies: molecular mechanisms and ipsc-based modeling of cartilage disorders. Archives of Stem Cell and Therapy, 6:6, Feb 2026. URL: https://doi.org/10.46439/stemcell.6.026, doi:10.46439/stemcell.6.026. This article has 0 citations.

Comprehensive Pathophysiology of Hypochondrogenesis: Molecular Mechanisms and Cellular Dysfunction in Type II Collagen Disorders

Hypochondrogenesis represents one of the most severe manifestations within the spectrum of type II collagenopathies, a group of rare genetic skeletal dysplasias caused by mutations in the COL2A1 gene encoding type II collagen[1][2]. This lethal form of short-limbed dwarfism is characterized by profound skeletal malformations, severe growth deficiency, pulmonary hypoplasia, and complications including hydrops fetalis, culminating in perinatal lethality[2][3]. The fundamental pathophysiological mechanism involves the production of structurally abnormal type II collagen molecules that fail to properly assemble into functional extracellular matrix structures, triggering endoplasmic reticulum stress, unfolded protein responses, chondrocyte apoptosis, and disruption of the critical endochondral ossification process[7][26]. Understanding the intricate molecular cascade from genetic mutation to clinical phenotype requires examination of multiple interconnected levels of biological organization, from gene-level mutations and protein synthesis abnormalities, through cellular stress responses and compromised signaling pathways, to tissue-level disruptions in bone and cartilage development that manifest as the distinctive clinical features of this severe skeletal dysplasia.

Classification and Relationship to Other Type II Collagenopathies

Hypochondrogenesis exists as part of a complex nosological spectrum of type II collagenopathies that includes achondrogenesis type II, severe spondyloepiphyseal dysplasia congenita, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, and Stickler syndrome[1][12]. The classification of these conditions has undergone significant revision as molecular and genetic understanding has advanced. Historically, hypochondrogenesis and achondrogenesis type II were considered distinct diagnostic entities based on radiographic criteria, but contemporary understanding recognizes these as manifestations of a phenotypic continuum with marked clinical and radiographic variability rather than as truly separate disease entities[4][15]. The distinction between hypochondrogenesis and achondrogenesis type II represents primarily a matter of severity and radiographic presentation, with both conditions resulting from mutations in the identical COL2A1 gene and sharing fundamental pathophysiological mechanisms[1][2].

The categorization of hypochondrogenesis within the broader framework of skeletal dysplasias or osteochondrodysplasias places it among more than 450 well-characterized heritable disorders that affect primarily bone and cartilage but can also significantly impact muscle, tendons, and ligaments[27]. Skeletal dysplasias are distinguished from dysostoses in that they represent generalized abnormalities in cartilage and bone development rather than localized abnormalities of specific skeletal elements. Hypochondrogenesis manifests as a generalized disorder affecting both endochondral and, to some extent, intramembranous ossification, with profound effects on the developing skeletal system at the earliest stages of fetal development[27].

The severity spectrum of type II collagenopathies depends substantially on the nature, location, and functional consequences of specific COL2A1 mutations. Missense mutations affecting glycine residues within the triple-helical domain produce the most severe phenotypes through dominant-negative mechanisms, whereas nonsense mutations and frame-shift mutations causing haploinsufficiency typically result in milder phenotypes[7][40]. Within this framework, hypochondrogenesis occupies the most severe end of the spectrum, rivaled only by certain instances of achondrogenesis type II, with approximately half of affected fetuses not surviving to term and nearly all affected infants succumbing within the immediate perinatal period[1][2][6].

The COL2A1 Gene and Type II Collagen Structure

The COL2A1 gene, located on chromosome 12, consists of 54 exons spanning over 31.5 kilobases and encodes the alpha-1 (α1) chain of type II collagen[7]. This gene provides instructions for the production of the α1(II) polypeptide chain, a 1060-amino acid residue protein that trimerizes with two additional identical chains to form the complete type II collagen homotrimer[7]. Type II collagen represents the quantitatively dominant collagen in hyaline cartilage, accounting for approximately 95% of total cartilage collagen and roughly 60% of the dry weight of adult cartilage tissue[7]. Beyond its predominance in cartilage, type II collagen is also a critical structural component of the nucleus pulposus of intervertebral discs, the vitreous humor of the eye providing optical clarity and structural support, and inner ear structures essential for auditory function[7].

The structure of type II collagen molecules reflects specialized architectural requirements for mechanical support and tissue integrity. Each α1(II) chain contains three structurally distinct regions: the N-terminal noncollagenous telopeptide comprising 19 amino acid residues, a large uninterrupted triple-helical domain containing approximately 1020 residues, and the C-terminal noncollagenous telopeptide consisting of 27 amino acid residues[7]. The triple-helical domain is characterized by the stereotypical Gly-X-Y tripeptide repeat pattern fundamental to collagen structure, where every third residue is a glycine positioned at the interior of the triple helix where space constraints permit only the small side chain of glycine, while the X and Y positions are frequently occupied by proline and hydroxyproline residues respectively[7].

The assembly of type II collagen molecules into functional extracellular matrix structures involves multiple coordinated processes. Initially synthesized as procollagen with pro-peptide extensions, the molecules undergo post-translational modifications including hydroxylation of proline and lysine residues, glycosylation, and disulfide bond formation within the endoplasmic reticulum before secretion[7]. Following secretion into the extracellular space, the pro-peptides are enzymatically cleaved to yield mature collagen molecules that spontaneously self-assemble into fibrils through electrostatic and hydrogen bonding interactions[7]. These collagen fibrils associate with other macromolecules including types IX and XI collagen and proteoglycans such as decorin, fibromodulin, and biglycan, which stabilize the larger fibril bundles to form mature collagen fibers[7]. This hierarchical assembly creates the organized three-dimensional architecture of cartilage matrix essential for the tissue's load-bearing and mechanical properties.

Molecular Mechanisms of Pathogenesis

COL2A1 Mutation Spectrum and Pathogenic Mechanisms

More than 400 distinct mutations in the COL2A1 gene have been identified in the medical literature and public genomic databases, comprising 329 pathogenic variants and 153 variants of uncertain significance[7][40]. The spectrum of mutations encompasses multiple molecular alteration types including point mutations (missense, nonsense, and splice site mutations), deletions, insertions, insertion-deletions, frame-shift mutations, and complex chromosomal rearrangements[7][40]. These mutations do not cluster at specific mutational "hot spots" within the gene; rather, they are distributed across the COL2A1 sequence, with their pathogenic consequences determined by the specific nature of the alteration and its position within the encoded protein[40].

Two principal molecular mechanisms underlie the dominantly inherited type II collagenopathies including hypochondrogenesis: dominant-negative effects and haploinsufficiency[7][40]. The dominant-negative mechanism, accounting for more than 70% of identified mutations and predominating in the most severe phenotypes, typically involves missense mutations that substitute a glycine residue within the triple-helical Gly-X-Y repeat with a structurally incompatible amino acid[7][40]. Because type II collagen functions as a homotrimer composed of three identical α1(II) chains, incorporation of even a single mutant chain into the assembled trimer can disrupt triple helix formation and destabilize the entire molecular complex[7]. This is particularly consequential because the chains assemble stochastically; if one-eighth of the α1(II) chains produced are mutant (expected for heterozygotes), approximately 70% of assembled trimers will contain at least one mutant chain and be non-functional[7].

Among the glycine substitutions, those involving replacement with larger, charged, or hydrophobic residues such as arginine, aspartate, glutamate, tryptophan, or valine produce more severe disruption of collagen assembly than those involving replacement with smaller residues such as alanine or serine[25][28]. Indeed, statistical analysis of COL2A1 mutations reveals a significant overabundance of Gly>Arg and Gly>Asp substitutions compared to rates predicted by sequence context alone, suggesting these represent particularly severe pathogenic variants subject to strong selection pressure in population genetics studies[25].

The positioning of glycine substitutions within the triple-helical domain carries significant consequences for disease severity. Substitutions occurring in the critical N-terminal region, particularly within Gly-X-Y triplets 10 through 15 of the triple helix, disrupt the early triple-helix nucleation and higher-order assembly process, producing more severe phenotypes than mutations in more C-terminal positions[25][28]. This clustering of severe mutations in the N-terminal triple-helical domain reflects the fundamental requirement for proper nucleation and initiation of the triple-helical structure, such that early perturbations have disproportionate consequences for overall collagen function[25].

In contrast, the haploinsufficiency mechanism, accounting for approximately 20-30% of type II collagenopathy mutations and generally producing milder phenotypes, results from nonsense mutations producing premature stop codons, out-of-frame deletions, or splice site mutations that result in non-functional mRNA and reduced synthesis of normal collagen protein[7][40]. The reduction in total collagen production, while impairing but not eliminating cartilage matrix formation, generally produces less severe disease than dominant-negative effects because the collagen that is produced retains normal structure and function[40].

Intracellular Retention, Endoplasmic Reticulum Stress, and the Unfolded Protein Response

The production of mutant type II collagen molecules initiates a pathological cascade centered on endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR). Detailed cellular and molecular studies have demonstrated that mutant procollagen molecules exhibiting glycine substitutions within the triple-helical domain fail to fold correctly, show reduced thermal stability compared to wild-type collagen, undergo excessive post-translational modifications including hyperhydroxylation and hyperglycosylation, and are retained within the endoplasmic reticulum rather than being secreted into the extracellular space[7][26][31].

The intracellular accumulation of misfolded procollagen causes progressive dilation of the rough endoplasmic reticulum cisternae and is associated with dilated vesicular structures containing accumulated protein[26][31][34]. Electron microscopy studies of cartilage from hypochondrogenesis patients reveal prominently dilated rough endoplasmic reticulum within all chondrocytes, containing fine granular material with occasional fibrils, consistent with accumulated misfolded collagen molecules[31][34]. These structural changes represent a cellular response to severe protein synthesis and folding stress.

The accumulation of misfolded proteins within the ER triggers activation of three canonical branches of the unfolded protein response mediated by three independent ER stress sensor proteins: inositol-requiring enzyme 1 (IRE1), activating transcription factor 6 (ATF6), and protein kinase R-like ER kinase (PERK)[29]. These three stress sensor proteins are normally maintained in an inactive state through binding to the molecular chaperone BiP (immunoglobulin binding protein, also called heat shock protein A5 or HSPA5). When misfolded proteins accumulate beyond the ER's folding capacity, they compete for and titrate away BiP from the ER luminal domains of the stress sensors, resulting in their activation[29].

Upon activation, each of these three pathways initiates distinct but complementary responses designed to restore ER protein folding homeostasis. The IRE1 pathway involves dimerization and trans-autophosphorylation of the kinase domain, triggering activation of a site-selective RNase domain that catalyzes unconventional splicing of XBP1 (X-box binding protein 1) mRNA, converting it from an inactive precursor form to the active XBP1s transcription factor, which translocates to the nucleus and upregulates transcription of ER-resident chaperone proteins and ER-associated degradation (ERAD) machinery[29]. The ATF6 pathway involves dissociation of ATF6 from BiP, allowing its transit to the Golgi apparatus where it undergoes proteolytic cleavage by site-1 and site-2 proteases (S1P and S2P) to generate the active ATF6p50 transcription factor, which similarly upregulates chaperone expression[29]. The PERK pathway involves phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) by the PERK kinase, which paradoxically reduces overall protein translation (thereby decreasing the protein folding load) while promoting translation of specific stress response genes including ATF4, another transcription factor that activates chaperone expression and ERAD genes[29].

In mouse models of COL2A1 mutations, all three UPR branches have been documented as activated in response to intracellular retention of mutant collagen[26]. Particularly in severe cases, the sustained accumulation of misfolded collagen overwhelming the ER's capacity to manage the protein folding stress results in prolonged or chronic UPR activation, creating conditions of chronic ER stress rather than the acute, self-limited stress response observed with other physiologic perturbations[26].

Chondrocyte Apoptosis and Growth Plate Disruption

Chronic endoplasmic reticulum stress and sustained unfolded protein response activation paradoxically shift from being protective mechanisms designed to restore cellular homeostasis to becoming pathogenic processes that trigger programmed cell death through apoptosis[26][29]. The progression from protective UPR activation to apoptotic cell death appears to depend on multiple factors including the intensity and duration of ER stress, the thermostability of mutant collagen molecules, and the efficiency of ER-associated degradation pathways in clearing misfolded protein accumulations[26].

Studies in a col2a1 p.Gly1170Ser knock-in mouse model demonstrated that homozygous mutant chondrocytes accumulate extensively misfolded procollagen in dilated ER cisternae, activate robust UPR responses, and undergo accelerated apoptosis prior to the normal hypertrophic differentiation stage[26]. This premature apoptosis appears to be the principal mechanism by which the mutation disrupts normal growth plate development and causes the severe skeletal dysplasia phenotype. In heterozygous mice producing the same col2a1 p.Gly1170Ser mutation, ER stress is activated and the UPR is engaged, but the stress intensity remains manageable and chondrocytes survive without undergoing apoptosis, explaining why heterozygotes typically display normal or near-normal skeletal phenotypes[26].

The molecular cascade linking ER stress to apoptosis in COL2A1-mutant chondrocytes involves multiple pathways. Prolonged PERK pathway activation maintains eIF2α phosphorylation, resulting in sustained suppression of translation but also chronic activation of ATF4-mediated transcription of pro-apoptotic genes[29]. Additionally, severe and sustained ER stress leads to BiP depletion from binding sites on JNK (c-Jun N-terminal kinase), allowing JNK activation and downstream signaling promoting apoptosis[29]. The IRE1-mediated splicing of XBP1, while initially promoting protective chaperone expression, under conditions of sustained stress can also activate apoptotic pathways[29]. Furthermore, excessive ER stress can trigger mitochondrial dysfunction through mechanisms including calcium release from ER stores, leading to opening of the mitochondrial permeability transition pore, release of cytochrome c, activation of the intrinsic apoptotic pathway through caspase-9 and caspase-3, and ultimate cell death[29].

The consequence of chondrocyte apoptosis in hypochondrogenesis is particularly severe because it occurs in the proliferative zone of the developing growth plate before chondrocytes reach the normal hypertrophic differentiation stage[26]. This results in marked reduction in proliferating chondrocytes, loss of the normal hypertrophic zone, and profound disruption of the organized columnar arrangement characteristic of healthy growth plates[4][26][31][34]. Histological examination of cartilage from hypochondrogenesis patients reveals hypercellular cartilage with decreased matrix deposition, numerous fibrous vascular canals traversing the tissue, and severely abnormal growth plate organization[4][31][34]. The dramatically accelerated chondrocyte death relative to matrix production creates a highly disorganized tissue architecture fundamentally incapable of supporting normal bone development.

Abnormal Collagen Fibrillogenesis and Extracellular Matrix Architecture

Even the mutant type II collagen molecules that manage to be secreted from chondrocytes despite ER stress display profound structural and functional abnormalities. Mutant collagen molecules demonstrate altered electrophoretic mobility when compared to wild-type collagen, suggesting charge and structural alterations[7]. Thermal stability studies reveal that mutant collagen exhibits markedly reduced thermostability, indicating that the triple-helical structure is inherently less stable than normal collagen and more prone to denaturation[7]. The slow rates of secretion of mutant collagen, with much remaining sequestered in the ER, results in markedly reduced quantities of mutant collagen in the extracellular matrix compared to the amount being synthesized[7].

The mutant collagen molecules that do reach the extracellular space exhibit severe defects in fibrillogenesis and matrix incorporation. Rather than assembling into properly organized collagen fibrils with normal periodicity and mechanical properties, the mutant molecules self-assemble into aberrant fibril structures of abnormal morphology[7][26][31]. Transmission electron microscopy reveals that these abnormal fibrils are structurally disorganized and unable to properly interact with other components of the extracellular matrix including other collagen types and proteoglycans[7][26].

This disruption of normal collagen fibrillogenesis has profound consequences for cartilage matrix organization and mechanical function. The extracellular matrix of cartilage in hypochondrogenesis is characterized by severely reduced density, with fewer collagen fibrils and diminished deposition of proteoglycans compared to normal cartilage[26][31][34]. The hierarchical organization of collagen fibrils—which in normal cartilage are oriented parallel to the articular surface in superficial zones and perpendicular to the surface in deeper zones, creating the characteristic "arcade-like" architecture that resists crack propagation—is completely disrupted in hypochondrogenesis[23]. Instead, the matrix appears relatively disorganized and lacking the structural integrity necessary to support mechanical loading and joint function.

Immunohistochemical studies have revealed additional abnormalities in the cartilage extracellular matrix composition in hypochondrogenesis. The staining intensity for type II collagen is markedly diminished, reflecting both the reduced amount of type II collagen in the matrix and the presence of partially degraded or abnormally modified collagen molecules that may not react normally with antibodies[31][34]. Notably, immunohistochemical staining reveals the presence of type I collagen in cartilage from hypochondrogenesis patients, which is normally absent from hyaline cartilage[31][34]. In situ hybridization studies demonstrate that chondrocytes from hypochondrogenesis patients simultaneously express both COL1A1 and COL1A2 genes (encoding type I collagen chains) alongside COL2A1, indicating abnormal gene expression patterns[54]. This ectopic expression of type I collagen in cartilage, likely stimulated by cellular stress responses and growth factor signaling alterations, represents a pathological reprogramming of chondrocyte gene expression reflecting the severe disruption of normal cellular function.

Disruption of Endochondral Ossification and Growth Plate Development

Hypochondrogenesis fundamentally disrupts the process of endochondral ossification, the normal developmental pathway through which most skeletal elements develop. In normal development, future long bones first form as miniature cartilage models during early fetal life. The cartilage model undergoes progressive replacement by bone tissue through a tightly orchestrated developmental program. This process begins with the appearance of a primary ossification center in the diaphysis (shaft) of long bones, where cartilage is progressively replaced by bone tissue formed by invading osteoblasts, while simultaneously osteoclasts resorb the newly formed bone to create the medullary cavity[50].

Later, secondary ossification centers form in the epiphyses (ends) of long bones, resulting in similar endochondral ossification that replaces cartilage with bone while retaining spongy bone architecture[50]. Upon completion of secondary ossification, the cartilage is almost entirely replaced by bone except for two regions: the articular cartilage that persists over joint surfaces and the epiphyseal plate (growth plate) located between the epiphysis and diaphysis, which continues to facilitate skeletal growth throughout childhood and adolescence[50].

Normal growth plate development involves coordinated differentiation of chondrocytes through distinct zones: the resting zone containing quiescent chondrocytes with round nucleus and minimal extracellular matrix; the proliferative zone with flattened, actively dividing chondrocytes arranged in characteristic columns; the hypertrophic zone containing enlarged chondrocytes that undergo terminal differentiation and eventually apoptosis; and the mineralized zone where matrix calcification occurs prior to vascular invasion and replacement by bone[7][22][50].

This orderly progression of chondrocyte differentiation is governed by intricate signaling pathways including Indian hedgehog (Ihh)/parathyroid hormone-related protein (PTHrP) signaling, transforming growth factor-β (TGF-β)/bone morphogenetic protein (BMP) pathways, fibroblast growth factor (FGF) signaling, Wnt/β-catenin signaling, and Notch signaling[21][22][49]. These signaling pathways depend critically on proper extracellular matrix composition, cell-matrix interactions mediated by integrins and other matrix receptors, and appropriate growth factor presentation through pericellular matrix microenvironments[7][22][23].

In hypochondrogenesis, this coordinated developmental program is severely disrupted at multiple levels. The defective type II collagen matrix itself cannot properly support chondrocyte development, as type II collagen acts not merely as a structural scaffold but as an active signaling molecule that regulates chondrocyte proliferation, differentiation, and survival through integrin-mediated signaling pathways[19]. In mouse models, loss of Col2a1 function accelerates chondrocyte hypertrophy through the bone morphogenetic protein (BMP)-SMAD1 pathway, as Col2a1 normally suppresses hypertrophy by competing with BMP receptors for binding to SMAD1 and inhibiting SMAD1 activation[19].

The severe reduction in proliferating chondrocytes due to enhanced apoptosis results in markedly shortened proliferative and hypertrophic zones[26][31][34]. Histological examination shows that the proliferative zone is nearly obliterated, with very few chondrocytes remaining to support progressive ossification[4][31][34]. This reduction in chondrocyte numbers prevents the normal accumulation of cartilage matrix required to serve as the scaffold for ossification.

Additionally, the chondrocytes that do survive show dysregulation of gene expression, with markedly reduced or absent expression of key markers of chondrocyte differentiation including COL2A1 itself, COL10A1 (encoding type X collagen characteristic of hypertrophic cartilage), Indian hedgehog, and Runx2 (a critical transcription factor for terminal chondrocyte differentiation and ossification)[7]. This dysregulation of chondrocyte-specific gene expression appears to result from endoplasmic reticulum stress-induced alterations in cellular signaling and transcriptional regulation, preventing normal progression through the differentiation program even in chondrocytes that survive the apoptotic cascade.

The result is a growth plate that is massively disorganized, hypocellular, lacks normal zonal organization, contains minimal extracellular matrix, and is essentially incapable of supporting progressive ossification[4][26][31][34]. The vertebral bodies and other bones that depend on endochondral ossification for their formation fail to ossify normally, appearing as non-ossified or hypoplastic structures on radiographs. The spinal vertebrae, sacrum, and pubic bones particularly show severe reduction in ossification, appearing as thin, poorly mineralized structures or remaining largely unossified[1][2][3].

Skeletal Manifestations and Clinical Phenotype

Limb and Trunk Abnormalities

The skeletal consequences of disrupted type II collagen-dependent development manifest clinically as severe short-limbed dwarfism. Affected infants have profound shortening of both the arms and legs with particularly severe involvement of the proximal segments (rhizomelic distribution), though the entire limb length is reduced[1][2][13]. The hands and feet are typically normal or nearly normal in size, creating striking body disproportion[1][2]. The severity of limb shortening is reflected in radiographic measurements; the femoral cylinder index (a measure of bone length relative to width) may be as low as 5.6-6.3 in hypochondrogenesis, compared to normal values around 3.5-4[4][31].

The trunk is markedly shortened with a small, narrow chest containing short, horizontal ribs that fail to ossify normally[1][2][3][13]. The ribs may show additional abnormalities including fractures or irregular ossification[1][3]. This thoracic hypoplasia has major clinical consequences, as the small chest cavity cannot accommodate normally-sized lungs and physically restricts pulmonary expansion. The severely reduced intrathoracic space creates the conditions for the severe pulmonary hypoplasia characteristic of the condition.

The abdomen appears enlarged or distended in many cases, which may be due to hepatomegaly or simply the relative prominence of abdominal contents in the context of a small thorax and shortened trunk[1][2][13]. In some cases, excess fluid accumulation in the abdomen occurs as part of broader hydrops fetalis, representing severe systemic edema and fluid accumulation in multiple body compartments[1][2][33].

Vertebral and Spinal Abnormalities

The spine is severely affected, with vertebral bodies showing marked deficiency in ossification[1][2][3]. Many vertebral bodies appear as thin, minimally ossified discs rather than normal robust vertebral structures. The intervertebral discs, which contain type II collagen as a component of the nucleus pulposus, may also show abnormalities. The sacrum, the fusion of the lowest vertebrae, similarly shows absence or severe reduction in ossification[1][2][3].

This abnormal spinal development has several clinical consequences. The instability and poor mineralization of vertebral structures creates risk for progressive spinal deformities. Additionally, in some cases, the malformed cervical vertebrae in the neck region can cause instability that increases risk for damage to the spinal cord, a particularly concerning complication that can occur even in infants who survive the perinatal period[38].

Pelvis and Hip Abnormalities

The pelvis shows marked dysplasia with hypoplastic (underdeveloped) ilia, which are the large hip bones[1][2]. The sacroiliac joints connecting the sacrum to the ilium are severely abnormal, and the overall pelvic architecture is profoundly disrupted. Additionally, the pubic bones frequently fail to ossify normally[1][2]. These pelvic abnormalities contribute substantially to the overall severity of the skeletal dysplasia and result in characteristic radiographic findings of a small, dysplastic pelvis.

Facial Features and Skull Abnormalities

The face appears distinctive, with characteristic features reflecting abnormal skeletal and cartilaginous development of facial structures. The face typically appears flat and oval-shaped rather than normally proportioned[1][2][13]. The eyes are widely spaced (hypertelorism)[1][2]. The chin is small (micrognathia) and appears recessed relative to normal proportion[1][2][13]. The forehead may appear prominent or bulging[1][3].

In some cases, an opening in the roof of the mouth occurs, termed a cleft palate[1][2][3]. The nasal bridge may be flattened[1][2]. Overall, the facial features result from abnormal development of the facial skeleton and cartilaginous structures that depend on type II collagen, creating the distinctive dysmorphic appearance recognized as part of the hypochondrogenesis phenotype.

Importantly, while facial structures show these abnormalities, the skull bones themselves (which develop through intramembranous rather than endochondral ossification) develop more normally than other skeletal elements, though even the skull may show some ossification abnormalities in the most severe cases[1][2].

Respiratory and Pulmonary Complications

The severe skeletal dysplasia results in critical pulmonary hypoplasia. Pulmonary hypoplasia refers to incomplete development of lung tissue, characterized by deficiency in airways, alveoli, and pulmonary parenchyma, resulting in reduced gas exchange capacity and respiratory insufficiency[14]. In hypochondrogenesis, the pulmonary hypoplasia is primarily secondary, resulting from mechanical compression of the thoracic cavity by the abnormally small and shaped chest combined with short ribs[1][2][3][14]. The skeletal dysplasia essentially prevents the lungs from expanding normally during fetal development, limiting the space available for normal lung growth and differentiation[14].

The lungs in hypochondrogenesis are markedly underdeveloped in terms of alveolar number, alveolar size, and pulmonary vascular development[14]. The reduced alveolar surface area critically impairs the capacity for gas exchange. Additionally, the narrow thorax may cause structural distortion of the airways and vascular structures. The combination of reduced lung parenchyma, impaired alveolar development, and thoracic constraint creates severe respiratory insufficiency that constitutes the primary cause of perinatal lethality in hypochondrogenesis[1][2][3][17].

Upon birth, affected infants immediately face severe respiratory failure due to the inability of their hypoplastic lungs to support oxygenation and ventilation adequate to meet metabolic demands. Despite intensive neonatal support including mechanical ventilation with high oxygen levels and positive pressure support, most infants cannot overcome the fundamental limitation imposed by severely underdeveloped lungs[1][2]. Some infants with hypochondrogenesis survive briefly with intensive support, but eventual respiratory failure occurs within days to weeks[2][4].

Hydrops Fetalis and Systemic Manifestations

Hydrops fetalis, also termed fetal hydrops, represents another important component of the hypochondrogenesis phenotype. Hydrops fetalis is a condition characterized by accumulation of excess fluid in at least two body compartments (commonly intracellular edema, pleural effusions, pericardial effusions, peritoneal ascites, and skin edema), resulting in severe generalized swelling of fetal tissues[33]. In hypochondrogenesis, hydrops fetalis can develop during fetal life in association with the severe skeletal dysplasia[1][2].

The pathophysiology of hydrops fetalis in hypochondrogenesis appears to involve multiple potential mechanisms. The severe thoracic hypoplasia and respiratory insufficiency may impair normal cardiovascular hemodynamics and fetal fluid balance. The cardiac abnormalities that can occur in some collagen disorders, including structural malformations of cardiac valves or myocardial dysfunction resulting from type II collagen abnormalities (as type II collagen contributes to cardiac connective tissue), could alter fluid dynamics. Additionally, the severe systemic effects of the collagen defect on multiple tissues may compromise normal fluid homeostasis.

The presence of hydrops fetalis has several clinical implications. Fetuses with severe hydrops in early pregnancy (before the third trimester) have particularly poor prognosis, with very high mortality rates[33]. Maternal complications can also develop, including a condition called maternal mirror syndrome in which the mother develops mirror manifestations of fetal hydrops including preeclampsia-like symptoms, severe fluid accumulation, and systemic symptoms[33]. In some cases, the detection of severe fetal hydrops during pregnancy prompts consideration of pregnancy termination[6].

Disease Spectrum and Severity Variation

Phenotypic Continuum with Achondrogenesis Type II

Contemporary understanding recognizes hypochondrogenesis and achondrogenesis type II as occupying a spectrum of phenotypic severity rather than representing distinct disease entities[4][15][18]. This recognition emerged from careful pathological and radiographic analysis of multiple cases, which revealed that radiographic findings displayed a fairly continuous spectrum of bony defects rather than two distinct radiographic syndromes[15]. The histological and ultrastructural findings are also similar between cases classified as hypochondrogenesis and those classified as achondrogenesis type II, being characterized in both by hypercellular, hypervascular cartilage with multiple small dilated cisternae of rough endoplasmic reticulum, confirming the shared pathophysiology despite the different diagnostic designations[4][15].

Cases originally classified as "mild achondrogenesis type II" and those classified as "severe hypochondrogenesis" are indistinguishable in their fundamental pathophysiology, with the historical distinction reflecting primarily radiographic severity differences and clinical presentation variability[15]. Some cases with radiographic findings positioned toward the mild end of this achondrogenesis-hypochondrogenesis spectrum have survived past the newborn period, at which point they are typically reclassified as having spondyloepiphyseal dysplasia congenita, a related disorder that also results from COL2A1 mutations but has somewhat different clinical features and better survival prospects[1][2][4].

Genotype-Phenotype Correlations

While no universally applicable genotype-phenotype correlations have been established for hypochondrogenesis and related type II collagenopathies, several important patterns have been documented[7][40]. Glycine substitutions within the triple-helical domain, particularly those in the critical N-terminal region comprising Gly-X-Y triplets 10-15, are associated with the most severe phenotypes including hypochondrogenesis and the most severe forms of achondrogenesis type II[7][25][28]. The specific amino acid substituted for glycine influences severity, with more hydrophobic or charged residues producing greater disruption of collagen assembly than smaller residues[25][28].

Nonsense mutations and frameshift mutations causing haploinsufficiency are generally associated with milder phenotypes than glycine-substituting missense mutations[7][40]. However, even this generalization has exceptions, as some truncating mutations have been reported to cause severe disease comparable to hypochondrogenesis[40].

An important observation is that identical mutations in the COL2A1 gene can occasionally produce phenotypic variability, with different patients harboring the same mutation showing somewhat different disease severity or clinical course[7]. This variability may reflect modifier genes, epigenetic differences, or stochastic factors affecting the severity of cellular stress responses and UPR activation. Such phenotypic variability even among patients with identical mutations underscores that while the COL2A1 mutation determines the fundamental pathophysiology, the ultimate clinical manifestation results from the interaction of the primary genetic defect with cellular and systemic factors modulating disease expression.

Prognosis and Natural History

Hypochondrogenesis carries uniformly poor prognosis, with nearly all affected infants resulting in perinatal lethality. The specific outcomes have been documented across multiple cases: some affected fetuses do not survive to term, resulting in stillbirth; among those born alive, most die immediately or within hours after birth from respiratory failure[1][2][4]. Some infants have survived for brief periods extending to several months, but these represent exceptional cases occurring with intensive medical support in tertiary centers[1][2][4].

The fundamental cause of perinatal lethality is respiratory failure resulting from severe pulmonary hypoplasia and thoracic hypoplasia. The underdeveloped lungs lack adequate alveolar surface area and gas exchange capacity to support oxygenation and ventilation sufficient to maintain life, even with maximal mechanical ventilatory support. Additional factors contributing to perinatal mortality include complications from the severe skeletal dysplasia, potential cardiac involvement or arrhythmias, and complications from hydrops fetalis when present.

Importantly, affected individuals do not live long enough to reach reproductive age and pass the condition to subsequent generations, despite the autosomal dominant inheritance pattern[1][2]. This restriction in reproductive potential means that virtually all cases of hypochondrogenesis result from new, de novo mutations occurring in the germline of unaffected parents, rather than inheritance from an affected parent.

Clinical Recognition and Prenatal Diagnosis

Prenatal diagnosis of hypochondrogenesis has become possible through multiple diagnostic modalities. Routine prenatal ultrasound may identify characteristic features including short limbs, narrow chest with short ribs, absence of normal ossification of vertebrae and pelvis, and in some cases, hydrops fetalis[6]. The distinctive skeletal findings on ultrasound, particularly in the context of a pregnancy with presumed normal parental history, should prompt consideration of lethal skeletal dysplasia[6].

Confirmatory imaging at tertiary high-risk pregnancy centers may include targeted ultrasound assessment, fetal MRI to further characterize skeletal and soft tissue abnormalities, and assessment of overall fetal wellbeing[6]. The comprehensive imaging assessment allows confirmation of the diagnosis and assessment of disease severity. When hypochondrogenesis is diagnosed prenatally, informed counseling regarding the lethal nature of the condition is typically provided to the parents, allowing them to understand the expected perinatal course and make informed decisions regarding pregnancy management[6].

Molecular genetic testing for COL2A1 mutations can confirm the diagnosis but is not necessary for diagnosis in the context of characteristic clinical and radiographic findings, and may not be prioritized in the acute prenatal setting when diagnosis is suspected. However, genetic testing provides valuable information for parents' understanding of disease etiology and for genetic counseling regarding recurrence risk, which is very low (essentially the background mutation rate) for sporadic de novo mutations but might be increased if germline mosaicism is present[2].

Current Understanding of Therapeutic Approaches

Despite the profound pathophysiology of hypochondrogenesis, there is currently no cure or specific disease-modifying treatment[1][2]. This reflects the fundamental nature of the genetic defect and the severe consequences of abnormal type II collagen production at the earliest stages of skeletal development. Management is therefore supportive and directed toward maximizing survival duration and quality of life for affected infants when they are born, with intensive neonatal support including mechanical ventilation, monitoring, and symptomatic treatment of complications.

However, emerging research has identified potential therapeutic targets that may have relevance to type II collagenopathies more broadly. Studies using induced chondrogenic cells and induced pluripotent stem cells derived from patients with type II collagenopathies have demonstrated that chemical chaperones such as 4-phenylbutyrate (4-PBA) can partially rescue cellular phenotypes by increasing secretion of type II collagen, reducing endoplasmic reticulum stress, and partially rescuing cells from apoptosis[9][45]. These findings suggest that molecular chaperone therapy might represent a future therapeutic avenue for type II collagenopathies, though significant challenges remain in terms of timing of intervention, achieving adequate tissue drug concentrations, and addressing the fundamental limitation that extensive skeletal malformations may already be established by the time intervention could be feasible[9].

Additionally, understanding of the signaling pathways dysregulated in type II collagenopathies, particularly the BMP-SMAD1 pathway and the various growth factor signaling cascades governing chondrocyte development, may eventually identify points of therapeutic intervention. For instance, agents that suppress pro-apoptotic signaling or enhance cellular stress responses might theoretically reduce chondrocyte apoptosis and improve skeletal development, though such approaches remain speculative and would require development and preclinical/clinical validation.

Conclusion

Hypochondrogenesis represents the severe end of a spectrum of type II collagenopathies resulting from mutations in the COL2A1 gene encoding type II collagen. The pathophysiology progresses through multiple interconnected levels of biological organization: at the molecular level, COL2A1 mutations produce structurally abnormal type II collagen molecules, particularly through dominant-negative glycine substitutions that disrupt the essential Gly-X-Y tripeptide repeat of the triple helix. These misfolded collagen molecules are poorly secreted, accumulate in the endoplasmic reticulum, and trigger sustained activation of the unfolded protein response through all three canonical ER stress sensor pathways. The chronic endoplasmic reticulum stress and unfolded protein response activation initiate apoptotic cascades that prematurely eliminate chondrocytes from the developing growth plates before they can complete normal differentiation.

At the cellular level, the consequence is severe disruption of chondrocyte function, marked reduction in chondrocyte proliferation and survival, dysregulation of chondrocyte gene expression including reduced expression of COL2A1 itself and other key chondrocyte differentiation markers, and disruption of the critical signaling pathways governing bone development. The extracellular matrix produced contains structurally defective collagen that cannot form normal fibrils or properly interact with other matrix components, creating a disorganized matrix incapable of supporting normal biomechanical function.

At the tissue level, these cellular and molecular abnormalities converge to produce severe disruption of endochondral ossification, the fundamental developmental process through which most skeletal elements form. Growth plates become severely disorganized and hypocellular, lacking normal zonal organization and containing minimal extracellular matrix. The result is failure of normal ossification of vertebral bodies, pelvic bones, and other skeletal elements, combined with severe short-limbed dwarfism reflecting the profound reduction in long bone length and the abnormal organization of growth plates.

At the clinical level, these tissue-level abnormalities manifest as the distinctive phenotype of hypochondrogenesis: severe growth deficiency with short limbs and trunk, narrow chest with short ribs, severe pulmonary hypoplasia, cranial and facial abnormalities, and in many cases, hydrops fetalis. Most critically, the severe pulmonary hypoplasia resulting from mechanical constraint of lung development by thoracic hypoplasia creates respiratory insufficiency incompatible with life, resulting in perinatal lethality from respiratory failure.

The recognition of hypochondrogenesis as occupying a phenotypic spectrum with achondrogenesis type II and other severe type II collagenopathies, rather than representing a distinct disease entity, reflects accumulating evidence that the fundamental pathophysiology is shared across these conditions, with phenotypic severity determined by factors including the specific COL2A1 mutation, the degree of disruption to collagen assembly and function, and the resulting intensity of cellular stress responses and disruption of skeletal development. Understanding this comprehensive pathophysiology from molecular mutation through cellular dysfunction to organismal-level disease manifestation provides the foundation for understanding this severe skeletal dysplasia and informs ongoing research toward potential future therapeutic approaches that might reduce disease severity in type II collagenopathies.